Knowledge From the Afrikan World, For the World

PMC Articles

Innovative Formulation Strategies for Biosimilars: Trends Focused on Buffer-Free Systems, Safety, Regulatory Alignment, and Intellectual Property Challenges

PMCID: PMC12196224

PMID:

Abstract

The formulation of biosimilar products critically determines their stability, safety, immunogenicity, and market accessibility. This article presents a novel integrative framework for biosimilar formulation that balances scientific, regulatory, and intellectual property dimensions, offering a holistic perspective rarely unified in the literature. It highlights the growing trend toward buffer-free, high-concentration systems that leverage protein self-buffering to improve patient comfort and formulation stability. The article also addresses regulatory flexibility from the FDA and EMA, which allows scientifically justified deviations from reference formulations to ensure pharmaceutical equivalence and minimize immunogenicity. A novelty of this article is its comprehensive analysis of how digital innovations, such as Quality-by-Design, Process-Analytical-Technology, and AI-based in silico simulations, are transforming formulation design and bioprocess optimization to reduce immunogenic risks and enhance bioequivalence. Two important key takeaways emerge: (1) strategic innovation in formulation, especially using buffer-free and high concentration systems, improve product stability and patient tolerability while complying with regulatory standards; and (2) intellectual property challenges, including patent thickets, strongly influence formulation decisions, making early legal-strategic alignment essential for market entry. The article confirms that practical recommendations for the selection of recombinant therapeutic protein formulations can effectively guide developers and regulators toward safer, more efficient, and commercially viable biosimilar products.

Full Text

Biosimilar medicines are highly sophisticated therapeutic products, specifically developed to replicate biological drugs of origin, while preserving quality, safety, and efficacy, but their intellectual property (patents) has expired [1]. Although they have similar characteristics to the source molecules, these are not identical; however, they are developed with the highest quality standards to match the safety and efficacy of the reference medicine used [2]. The process of developing biosimilars is exceptionally complex because it must address the inherent variability of recombinant proteins and ensure that any differences from the original product are clinically insignificant [3,4]. A fundamental element in the development and production of biosimilars involves the integration of advanced process design, control, and analytical characterization techniques (Quality-by-Design (QbD), Process-Analytical-Technology (PAT), in silico modeling) to anticipate immunogenic risks and optimize bioequivalence, which allows the reduction in uncertainty and simplifies regulatory reviews [5]. In the formulation of biosimilars, there are key components, including stabilizers and excipients, which must also meet the highest quality standards [6,7]. These stabilizers and excipients can profoundly influence the biopharmaceutical profile of the resulting biosimilar, which must also include the shelf life of the new medicine, as well as the method of administration, the efficacy in the treatment of patients, and the potential for immunogenicity [7,8]. Likewise, some innovations such as buffer-free formulations and nanomedicine approaches illustrate how the field of biosimilars is evolving to overcome conventional challenges while improving patient outcomes [9]. All these components, together with the inherent variability of recombinant proteins, play a fundamental role in maintaining the stability and activities of therapeutic proteins, which must be estimated from the beginning of the formulation as fundamental components of the success or failure of the final biosimilar product [10,11,12].
In this complex dynamic, there is one crucial element to consider, that is, the expiration of intellectual property protection, which includes patents. These protect the inventors of the original biological molecules from copying for a period of two decades [1,2]. During this time, the original biological drugs enjoyed a kind of monopoly, which resulted in very high prices for low-income patients and limited their access to effective treatments [13]. Once the patent has expired, it is possible to develop and market biosimilars. Their main attraction lies in their potential to significantly reduce treatment costs without compromising quality standards, as the pharmaceutical companies that manufacture the biosimilars do not have to face royalty payments associated with patent protection or extensive clinical trials with the same duration as the originals [14,15,16,17,18,19,20]. These economic implications related to biosimilars further reinforce their relevance in the market, where they correlate with lower drug prices and increased access to proven therapies that otherwise might have been prohibitively expensive for low-income patients [21,22].
The clinical transition from an original biological drug to a biosimilar can be positively influenced by socioeconomic factors [1]. In fact, since biosimilar products have characteristics similar to their reference counterparts, they are marketed at lower cost, among other things, because of the absence of royalties on intellectual property rights. Likewise, those who access these products generally come from communities with more restricted economic resources (as is the case in many Latin American and African countries); this would facilitate access to first-class medical treatments for these more disadvantaged communities at a much lower cost than IP-protected originals. Furthermore, cost-effectiveness analyses have shown that the strategic implementation of biosimilars could alleviate financial stress on healthcare systems, particularly in economically diverse regions [23,24]. Data reveals that biosimilars can offer substantial reductions in drug spending while maintaining therapeutic efficacy, ultimately improving patient outcomes in chronic disease management protocols [25,26]. Countries that have implemented biosimilars in their treatment protocols have achieved significant savings in final costs, which can be used to improve patient services or to cover more patients within existing budgets [27,28]. Data reveals that biosimilars can offer substantial reductions in drug spending while maintaining therapeutic efficacy, ultimately improving patient outcomes in chronic disease management protocols [25,26]. Countries that have implemented biosimilars in treatment protocols have seen significant final cost savings, which can be redirected to improve patient services or cover more patients within existing budgets [27,28]. This process contributes to the sustainability of healthcare systems by ensuring the quality, safety, and efficacy of biosimilars, optimizing the use of resources by offering more affordable alternatives to low-income patients [29]. However, despite the promising health and economic implications for patients, the complexities of biosimilar manufacturing pose specific challenges. Each biosimilar manufacturer must independently develop specialized cell lines and optimized production protocols capable of consistently producing biologically comparable products [1]. Therefore, the development of biosimilars represents both a scientific achievement and a complex regulatory challenge, highlighting the importance of maintaining strict standards of quality and efficacy as these drugs become increasingly integrated into global healthcare practices [20].
Biosimilars differ primarily from generic drugs in both their production and regulatory approval, as can be seen in the explanation in Table 1.
Therefore, generic drugs are small-molecule compounds synthesized through well-defined chemical processes that allow identical replication of the active pharmaceutical ingredient (API) [3,30,31]. This means that their regulatory approval only requires a demonstration of bioequivalence, that is, that the generic releases the same amount of API into the bloodstream as the reference product, without the need for clinical trials to evaluate efficacy or immunogenicity [1,2].
In contrast, biosimilars are large and structurally complex proteins (typically 10,000 to 300,000 Da) produced in living cell systems using recombinant DNA technology [1]. These biological systems introduce natural variability (e.g., glycosylation, folding, impurities), making exact replication of the originator biologically impossible. Therefore, biosimilars must demonstrate high similarity, and not be identical, to their reference products. Approval is based on a stepwise comparability exercise, beginning with extensive physicochemical and functional characterization of critical quality attributes (CQA), followed by non-clinical and comparative clinical studies, particularly for immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD).
To ensure therapeutic equivalence, in the United States and Europe, biosimilars undergo a stepwise comparability assessment mandated by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), which includes in-depth characterization (e.g., glycosylation, folding), mechanism-of-action confirmation, and clinical immunogenicity studies. Regulatory frameworks from the EMA and FDA apply the ‘totality of evidence’ principle, requiring integrated data from analytical, functional, and clinical domains [2]. Furthermore, biosimilars are not automatically considered interchangeable, since separate regulatory determination is often required for substitution at the drug level, especially in jurisdictions such as the United States. This high regulatory bar reflects the complexity of biologics and the need to ensure therapeutic equivalence despite minor molecular differences. Although biosimilars share identical primary protein sequences and closely conform to three-dimensional configurations critical for biological activity, slight variations in their complex structure inevitably occur due to differences in production processes [32]. These structural nuances require strict regulatory oversight to ensure the therapeutic equivalence of biosimilars with their reference counterparts in terms of efficacy, safety, and quality [33]. Therefore, regulatory frameworks must intervene in rigorous analytical characterization, examining molecular weight, isoforms, impurity profiles, and biochemical attributes using advanced analytical technologies [34,35]. Equally important are comparative clinical studies that evaluate pharmacokinetics, pharmacodynamics, immunogenicity, and overall safety, confirming the clinical comparability of biosimilars with the original biological products [36].
Advanced biosimilar development integrates cutting-edge design, manufacturing, and testing to meet stringent US and EU regulatory requirements. Biosimilars are approved through abbreviated regulatory pathways established by the EMA since 2005 and the FDA through the Biologics Pricing Competition and Innovation Act (BPCIA) of 2009 [1]. These frameworks require robust comparative evidence demonstrating similarity to a reference biologic in terms of quality, efficacy, and safety, while allowing reduced clinical trial burden. By 2023, more than 100 biosimilars had been approved in Europe and the US, including high-impact therapeutic areas such as oncology, rheumatology, and endocrinology [2].
Analytical characterization, using approaches such as mass spectrometry, surface plasmon resonance, and chemometrics, is critical to establish structural and functional similarity to the reference product [37,38]. In manufacturing, different process development strategies, such as the design of experiments and PAT, facilitate important mechanistic control and characterization, ensuring product consistency during scale-up [39,40]. Regulatory pathways are increasingly using innovative analytical data and AI-based models to address various challenges, streamline comparability assessments, and reduce overreliance on large clinical trials [2]. Complementary studies demonstrate that the integration of advanced analytics and digital manufacturing improves both quality control and cost effectiveness in the final production of biosimilars [41].
Real-time monitoring strategies such as online FTIR and Raman spectroscopy, as part of the PAT framework, ensure that critical quality attributes are maintained within acceptable limits, thus supporting the clinical performance of biosimilars [40,42]. At the same time, QbD initiatives and digital automation, supported by AI analytics, enable biosimilar manufacturers to more efficiently monitor their performance through US and EU regulations to rigorously assess comparability with reference products, optimize process development, and improve future scale-up strategies [2].
For the documentary search, a variant of the PSALSAR methodology was used (Protocol–Search–Appraisal–Synthesis–Analysis–Report) [43]. This methodology offers a rigorous, transparent, and reproducible framework that allows an in-depth evaluation of the most representative systematic review of the literature, allowing the collection of a complete collection of documents related to the aspects investigated and that guide future scientific research [44,45,46,47,48].
The PSALSAR methodology is applicable in the multispectral domain of biosimilar formulation research, where technological, regulatory, and legal frameworks converge. Its structured approach addresses the complex interactions between pharmaceutical formulation, regulatory science, and intellectual property, facilitating a comprehensive review of the literature that enhances methodological rigor and narrative cohesion [3,5]. Unlike traditional systematic reviews focusing solely on clinical outcomes, PSALSAR supports an argument-driven synthesis that effectively integrates formulation-related aspects such as buffer selection, along with regulatory considerations such as QbD and PAT [3]. The distinction of this methodology lies in its adaptability, which allows it to synthesize various types of content (scientific, regulatory, and legal) while allowing deeper interpretative analysis that goes beyond mere data aggregation, ultimately allowing for in-depth research into biosimilar formulations.
The methodological process began with an exploratory phase based on the research objective, in which representative keywords of the thematic domain addressed in this systematic review were defined [49]. These keywords were selected for their high scientific relevance, their ability to effectively delimit the universe of study, and their methodological usefulness in establishing inclusion and exclusion criteria, in accordance with the principles of transparency and reproducibility established by the PRISMA methodology. To guarantee effective and specific document retrieval during the identification phase, a set of strategic keywords was defined that allowed the search to be precisely and systematically guided through scientific databases and search engines with high scientific visibility, such as Scopus, Web of Science, Science Direct and Google Scholar, Core Collections, Science Direct, Compendex, Derwent, Google Scholar, Innovation Index and GeoIndex. These sources were complemented by interdisciplinary research tools that expanded the coverage and precision of the results obtained. To this end, both controlled and uncontrolled terms were integrated using Boolean operators and truncation strategies. Keywords used were the following: “Biosimilars”; “Biology”; “Biotechnology”; “High-concentration formulations”; “Buffer-free systems”; “Immunogenicity mitigation”; “ Excipients”; “Quality by Design (QbD)”; “ In silico simulations”; “Process Analytical Technology (PAT)”; “Food and Drug Administration (FDA)”; “ European Medicines Agency (EMA)”; “Intellectual property strategies (IP)”; “Artificial Intelligence (AI)”. Each of these words was selected for its relevance using “AND” and “OR” to capture the central dynamics of the object of study, covering regulatory, technological, clinical, and legal aspects linked to the development and formulation of biosimilars. Likewise, they were formulated in English to maximize coverage in the high-visibility scientific databases used.
Table 2 provides a more detailed analysis of the inclusion and exclusion criteria used to select the references ultimately used in the research. These criteria are established prior to the bibliographic search based on the identified keywords to reduce bias and ensure that the document selection process is systematic and reproducible.
The review process incorporates a flow chart represented in Figure 1, which illustrates the selection procedure, including the number of studies identified, selected, and involved, as well as the reasons for exclusion at each stage. The documentary strategy included a systematic review from 2019 to 2025, which resulted in a repository of 2193 documents (32 websites). This repository offers a representative sample of the state of the art on the most innovative research topic and integrates perspectives from different disciplines with an emphasis on the formulation of biosimilars in the current and future biopharmaceutical context.
The design, manufacturing, and subsequent analytical characterization of biosimilars play an important role in establishing confidence in these products and in ensuring that critical quality attributes reflect those of the reference product like observed on Table A1. Biosimilar development involves not only replicating the primary amino acid sequence but also mimicking post-translational modifications such as glycosylation, which are essential to maintain clinical efficacy and safety and thus ensure that CQAs remain within acceptable ranges [50,51]. Continuous improvements in process design, including real-time monitoring and QbD initiatives, have become a cornerstone of biosimilar development [52]. The application of QbD in conjunction with the design of experiments (DoE) establishes defined control strategies and design spaces, ensuring consistent process performance and product reproducibility [37,53,54]. The use of PAT and real-time monitoring, complemented by advanced chemometric analysis, facilitates an accurate assessment of both upstream and downstream processes [55,56]. As manufacturing processes become increasingly automated and deep data-driven, the integration of machine learning for pattern recognition further improves the control of the entire process [57].
Controlled downstream processing is essential for biosimilar manufacturing, as it ensures that chromatographic purification meets strict quality requirements [58]. Advanced analytical technologies, such as ultrafiltration/diafiltration and multimodal chromatography, facilitate the high-resolution separation of aggregates and impurities from the process, thus improving the purification accuracy during scale-up [39,59].
Post-translational modifications (PTMs), such as glycosylation, phosphorylation, deamidation, and oxidation, significantly influence the stability, efficacy, and immunogenicity of biologics, including biosimilars. Unlike conventional drugs, biosimilars are produced in living cells, leading to variability in PTM profiles, which can impact critical aspects such as receptor binding, clearance rates, and antibody-dependent cellular cytotoxicity (ADCC) [60].
The achievement of consistent PTM profiles is complex due to the different expression systems and the variable bioprocessing conditions, which require advanced analytical techniques such as liquid chromatography tandem mass spectrometry (LC-MS/MS) and capillary electrophoresis for thorough characterization [61]. Immunogenicity remains a concern, as even slight differences in PTM can provoke adverse immune responses, potentially compromising therapeutic effectiveness [62]. Even small differences in glycosylation profiles (e.g., sialylation or fucosylation) can alter pharmacokinetics and affect receptor binding affinity, clearance rates, and effector functions such as antibody-dependent cell cytotoxicity (ADCC) [63].
These factors mean that biosimilar developers must implement advanced analytical technologies (e.g., LC-MS/MS, capillary electrophoresis) to rigorously characterize PTMs and demonstrate high similarity to the reference product [64,65].
Regulatory bodies (FDA and EMA) demand comprehensive comparative studies that assess immunogenicity, recognizing the importance of minimizing aggregates and choosing appropriate excipients [66,67,68].
The formulation and long-term performance of biosimilars are crucial to their therapeutic success in a highly competitive industry. Molecular design in biosimilar development emphasizes engineering expression systems that closely resemble the reference biologic. Techniques such as optimizing codon usage and designing suitable signal peptides are vital to achieve biochemical equivalence with the innovator [69]. However, due to the inherent complexity of biologics, the achievement of identical molecular structures is implausible. Instead, a rational engineering approach focuses on replicating functional domains that dictate therapeutic efficacy [70].
Reproducing PTMs, especially glycosylation, is particularly challenging. As PTMs significantly influence the pharmacokinetics and immunogenicity of biologics, meticulous control over production conditions is necessary [71]. Advanced analytical techniques, including LC-MS and HILIC, facilitate comparative glycosylation profiling, which is essential to establish biosimilarity [72]. Furthermore, strategies such as the use of nanoparticles for stabilization hold promise to enhance the delivery and efficacy of sensitive biosimilar products [73].
Molecular design in biosimilar development requires meticulous attention to protein structure and function, particularly focusing on how recombinant expression systems and upstream processes can replicate the characteristics of reference biologics [74]. This intricate process emphasizes the role of signal peptides in facilitating proper protein folding, the optimization of codon usage for effective expression in host cells, and the selection of appropriate expression systems to closely align with the glycosylation profiles of the reference products. While achieving complete molecular identity is unattainable due to the inherent complexities of biologic synthesis, molecular engineering strategies aim to reproduce the key functional domains critical for therapeutic activity and receptor interaction [2,75].
The creation of biosimilars must account for variations in PTMs, with glycosylation being one of the most significant challenges faced in this developmental landscape. Glycans, which are carbohydrate structures attached to proteins, can affect the biological function, stability, immunogenicity, and half-life of the resultant biosimilars. This complexity arises from the sensitivity of glycosylation to cellular environments, including cell type, medium composition, culture conditions, and purification processes, which can dramatically influence glycan structure [76]. As such, developers utilize orthogonal methods alongside extensive CQA modeling to verify that the PTM profiles align closely with those of the reference biologic [77,78].
Advanced analytical techniques such as liquid chromatography mass spectrometry (LC-MS), nuclear magnetic resonance (NMR), and high-resolution chromatography play critical roles in ensuring that the molecular architecture and post-translational landscapes of biosimilars are consistent and comparable to their reference products. These methodologies facilitate detailed examination and characterization of glycosylation patterns and other critical quality attributes, supporting rigorous testing and validation protocols that are essential for regulatory approval [72,79]. For example, methods such as mass spectrometry allow precision in identifying glycosylation sites and structures, thus confirming conformity to established specifications set by authorities such as the FDA [68].
The variability inherent in PTMs necessitates a robust approach to verifying these modifications, as even minor discrepancies can translate into considerable differences in therapeutic efficacy and safety profiles. Researchers have proposed using sophisticated algorithms and automation to streamline the analyses of glycosylation and other PTMs during the biosimilar development process. This could improve the reliability of assessing biosimilarity and contribute to more consistent product quality [2,80].
Although challenges remain with respect to glycosylation consistency, advancements in nanomedicine also present exciting avenues for addressing the stability and delivery of biosimilars. Nanotechnology, which includes approaches such as nanoparticle encapsulation or liposomal carriers, serves to protect sensitive biologics from environmental degradation while enabling sustained release mechanisms. Such strategies can potentially mitigate issues related to immunogenicity while also improving pharmacokinetic profiles [81]. The ongoing integration of nanotechnology into biosimilar formulations reflects a growing recognition of the potential it holds for the next generation of therapeutic interventions.
Moreover, through ongoing research into glycomic profiling and enhanced production techniques, it is increasingly plausible to generate biosimilars that mimic their originators more closely. This includes the manipulation of culture conditions, bioreactor designs, and even the use of plant-based production systems that facilitate the expression of complex glycosylated proteins [69,82]. Innovative analytical strategies will continue to evolve, providing pathways to not only replicate but also optimize these characteristics dynamically throughout the development process [83].
The regulatory landscape remains a key component in the development and approval of biosimilars. Authorities are focused on ensuring that these products not only meet safety and efficacy benchmarks but also provide transparency and consistency in quality control [84]. With continuing advancements in biotechnology and analytical methods, along with strong regulatory frameworks, the outlook for biosimilars appears promising. The convergence of rigorous analytical methodologies and innovative molecular design will be crucial in the delivery of clinically effective and safe biosimilar therapies to patients around the world [85,86].
The analytical characterization of biosimilars has become increasingly sophisticated with the implementation of orthogonal techniques that investigate various aspects of molecular structure [37]. This employs an integrated ‘totality of evidence’ strategy that uses high resolution mass spectrometry, as well as multidimensional LC-MS (or liquid chromatography coupled to multidimensional mass spectrometry), which is an advanced analytical technique that combines several chromatographic separation steps with mass spectrometry (MS) to achieve a more precise, in-depth, and complete characterization of complex chemical mixtures, such as proteins, metabolites, lipids or natural extracts [87]. LC-MS methods enable high-resolution analysis of intact proteins, peptide mapping, and glycan profiling in a single workflow [88]. This multiplexing capability is essential for biosimilars, where even small differences in post-translational modification patterns can have significant immunogenic implications. Orthogonal approaches ensure that differences in charge variants and glycan profiles, which are critical quality attributes, remain within acceptable ranges as required by regulatory authorities in both the United States and Europe [37,50,89]. Advanced nuclear magnetic resonance spectroscopy (NMR) techniques, bidirectional heteronuclear (bidirectional heteronuclear NMR or bidirectional heteronuclear correlation NMR), which is a specialized NMR technique that correlates nuclei of different chemical elements to more accurately analyze molecular structure, allowing to analyze how distinct nuclei connect in both directions within a molecule [21]. All these techniques facilitate a deeper understanding of the chemical structure and are especially valuable in complex structural analyses such as those of biomolecules, improving spectral interpretation and assignment to reveal subtle variations in glycosylation and higher order structures [90,91,92]. Furthermore, statistical methods such as bootstrapping tests have improved confidence in biosimilarity assessments, ensuring batch-to-batch consistency and mitigating process-induced variations [93]. Together, these advanced physicochemical and functional analyses support the reliable development of biosimilars by providing a robust framework for confirming safety and efficacy at the molecular level [94].
Advances in manufacturing also include the adoption of continuous processing strategies and real-time release testing enabled by PAT. Advances in manufacturing have benefited significantly from the integration of miniaturized PAT into continuous processing systems [95]. These advances enable the real-time detection of critical quality attributes such as protein aggregates and glycosylation variants, facilitating the implementation of immediate corrective actions and reducing batch-to-batch variability [40,96]. Incorporation of online tools, such as Raman spectroscopy, facilitates process monitoring, ensuring that design deviations are addressed quickly [97,98]. Biosimilar analysis similarity assessments are now recognized as a comprehensive exercise that focuses not only on physicochemical properties but also on functional performance of the molecule [3]. Some novel methods were used, including multifaceted bioassays and cell-based studies, to assess biological activity against the reference product. Such studies are vital for the acceptance of biosimilars by regulatory authorities in both the US and European markets as they establish a direct link between manufacturing quality and clinical outcomes. This ‘totality of evidence’ approach ensures that any subtle manufacturing differences do not translate into clinically meaningful differences.
QbD is integral to biosimilar manufacturing, as it emphasizes the identification of critical quality attributes (CQAs) and their alignment with critical process parameters (CPPs). This strategic change enhances the robustness of the production process, mitigating variability and ensuring that the biosimilar meets regulatory requirements [99,100]. Furthermore, PAT improves QbD by allowing continuous real-time monitoring of critical parameters during manufacturing, ensuring consistent quality between batches [101].
Glycosylation is crucial for the characterization of biosimilars, significantly influencing their pharmacokinetics, efficacy, and immunogenicity. Regulatory authorities require comprehensive glycan profiling through advanced analytical techniques to establish bioactivity and comparability with the reference product, reinforcing the importance of glycosylation in the evaluation of biosimilars [53]. Collectively, QbD, PAT, and glycosylation profiling are pivotal in supporting the development of safe and effective biosimilars that meet stringent regulatory standards.
Furthermore, advanced end-point assays such as multiangle light scattering (MALS), differential scanning calorimetry (DSC), and dynamic light scattering (DLS) have improved the ability to monitor biosimilar thermal and colloidal stability, as well as aggregates and subtle conformational changes induced by manufacturing stress, thus ensuring batch consistency and strengthening quality control during process validation [102].
Orthogonal analytical approaches are vital in verifying biosimilarity due to the complexities inherent in biological products. These approaches utilize multiple independent methods, such as DSC, MALS, and DLS, to assess critical attributes of biosimilars. When employing these diverse techniques, the risk of bias of a single method is mitigated, thus strengthening the validity of claims of biosimilarity [103].
DSC measures the thermal transitions of proteins, providing insight into their thermal stability and folding integrity, which are essential for confirming identical functional characteristics between a biosimilar and its reference product [104]. MALS, combined with size-exclusion chromatography, enables the determination of absolute molecular weight and aggregation state, critical for ensuring physicochemical equivalence [105]. DLS focuses on the size distribution and colloidal stability of particles, allowing for early detection of aggregation phenomena that could affect therapeutic efficacy [37,103].
Together, these techniques provide a comprehensive dataset that supports regulatory compliance and the totality-of-evidence approach mandated by regulatory agencies, ultimately facilitating the biosimilar approval process [5,106].
Integration of these orthogonal assays with high-resolution structural characterization methods, particularly X-ray crystallography and cryoelectron microscopy, further allows detailed mapping of the 3D conformation of the protein, crucial for verifying biosimilarity and shelf-life stability [107,108].
To facilitate a practical understanding of how digital tools integrate with regulatory-aligned formulation design, Figure 2 illustrates a stepwise flow of QbD–PAT–AI integration in biosimilar development. This system approach enables real-time feedback, rational formulation optimization, and predictive analytics for critical quality attributes.
Table 3 complements Figure 2, allowing a more detailed understanding of the sequential steps and digital tools involved in the workflow of integrated biosimilar formulation with QbD-PAT-IA.
The integration of AI and machine learning is transforming biosimilar development by analyzing large-scale manufacturing and datasets to predict critical quality attributes and detect process anomalies early [2,37,109]. AI-based systems improve process design by facilitating predictive quality assessments like those developed for originator manufacturing, now extending to analytical similarity of biosimilars and optimization of culture media [110]. Moreover, by evaluating parameters such as glycosylation patterns, these computational tools support robust process validation and agility in production environments, ensuring that product quality consistently meets regulatory standards [111,112]. AI facilitates real-time process monitoring and control in biosimilar production by integrating advanced analytics with PAT systems to analyze bioprocess data streams, improving adaptive feedback mechanisms that minimize variability and optimize yields [2,113]. Although still in the early stages, the convergence of these advanced techniques promises to optimize process variables, thereby reducing deviations and accelerating scale-up while advancing quality control measures in biosimilar development [37,114]. Integration of digital tools and AI in the formulation of predictive models and in silico simulations represents a transformative advance that spans multiple sectors, from the discovery of new drugs to the optimization of industrial processes. Recent advances in AI, such as the multihead attention-based drug repurposing recommendation network (MRNDR) model, demonstrate the potential of multihead attention mechanisms in the prediction of complex biological interactions [115]. The model uses a large-scale dataset and advanced machine learning techniques to predict drug-disease relationships, achieving state-of-the-art performance metrics. Although the primary focus is drug repurposing, the methodologies employed, such as multi-head self-attention mechanisms and weighted representation distance scoring, are relevant to biosimilar formulation optimization. These techniques can improve the prediction of protein stability, aggregation propensity, and immunogenicity, which are critical factors in the development of biosimilars. While MRNDR is primarily applied to drug repurposing, its underlying architecture can be adapted to predict critical quality attributes in biosimilar formulations, thus enhancing the efficiency and accuracy of formulation development processes. This convergence is based on the ability to create digital twins that replicate the behavior of real systems in virtual environments, allowing the simulation, analysis, and prediction of different scenarios without incurring high costs and risks inherent to physical tests [115,116,117]. In biosimilar development, a digital twin is used, representing a virtual real-time replica of the bioprocess derived from mechanistic models and sensor data, to simulate and predict the impact of process changes on CQAs before execution, streamlining the QbD approach [101,118].
Deep learning models, particularly convolutional neural networks (CNNs) and recurrent neural networks (RNNs), play a significant role in forecasting protein aggregation during formulation processes. By analyzing large datasets of molecular structures and properties, these models can effectively identify aggregation-prone regions, helping guide excipient selection and thus mitigate immunogenicity risks and improve biosimilar stability over time [2,119]. In the pharmaceutical field, the use of transformer-based models has been developed to estimate drug-target interactions, significantly optimizing the discovery and validation process of potential compounds [120]. Approaches used in silico for the design and prediction of aptamers improve efficiency in the identification of biomarkers and therapeutic optimization [121]. In silico simulations allow exploring multiple scales, from molecular processes to macrolevel systems, using mathematical modeling methods combined with AI algorithms. These techniques have been extended to the simulation of complex interactions in antibody-based therapies, where the integration of multiscale models is crucial to understand the relationship between molecular structure and process behavior at the production level [122]. In silico simulations are increasingly pivotal in the design of aptamers and in the optimization of therapeutic processes. By employing molecular coupling and dynamic simulation algorithms, researchers can accurately predict aptamer-target interactions, refine binding affinities, and enhance target specificity without extensive physical experimentation, thus streamlining the development of these biomolecules for therapeutic purposes [123]. This modeling approach not only reduces costs and time but also helps in the preassessment of aptamer viability as diagnostic tools or therapeutic agents. Predictive modeling is crucial for scaling up biosimilar manufacturing because pilot-scale performance often does not translate directly to larger scales. Mechanistic and statistical models simulate critical bioprocess variables, such as shear stress and oxygen transfer rates, enabling developers to anticipate quality attributes and operational challenges before industrial implementation [124]. This predictive capacity minimizes risks, improving the reliability and efficiency of scaling operations. Single-use bioreactors enhance the safety of biosimilar production by significantly reducing cross-contamination risks associated with traditional systems. Their design eliminates the need for extensive cleaning and sterilization procedures between batches, promoting contamination control and operational efficiency, particularly in multiproduct facilities [125]. By facilitating rapid changeovers and offering greater flexibility, single-use systems support agile manufacturing practices essential for modern biosimilar production. Integrating ‘in silico’ approaches in drug discovery not only reduces the time and cost of experimental testing but also allows the prediction of complex behaviors and iterative adjustment of designs [126]. In this context, the application of silico models not only allows simulation of complex scenarios at different scales but also improves the efficiency and effectiveness of the development process by reducing experimentation time and associated costs and facilitating early validation of hypotheses before physical implementation [127,128].
Advances in deep learning, particularly in the application of graph neural networks (GNNs), have proven to be very important in modeling molecular structures and predicting their properties with high precision [129,130]. Similarly, a multiscale graph neural network model that integrates features at different levels of the molecular structure to predict properties with comparable or superior performance compared to other methods [131]. These approaches allow for a detailed characterization of the molecular structure, offering a solid basis for optimization in the development of biosimilars [128]. The use of GNN-based approaches to map protein-protein interfaces allows us to optimize the compatibility and functionality of biosimilars by predicting critical molecular interactions [132].
Another crucial aspect is the improvement in the accuracy of predictive models through the fusion of deep learning techniques. learning e, 3D structural information. By incorporating graph neural networks together with models based on three-dimensional structure, it is possible to predict the binding affinity between ligands and proteins more accurately [133]. This methodology is especially relevant in the context of biosimilars, where optimization of molecular interactions directly influences therapeutic efficacy and similarity. Similarly, encoder–decoder models improve target-directed design, accelerating the identification of desired molecular profiles and reducing uncertainty at critical stages of development [134].
Integration of digital platforms and AI tools into biosimilar formulation workflows enhances molecular stability and design efficiency. For example, simulations such as GastroPlus® and ADMET Predictor® by Simulations Plus facilitate pharmacokinetic predictions and excipient compatibility assessments, which are crucial for biopharmaceutical developments [135]. AI advancements, particularly AlphaFold’s ability to predict protein structures, are increasingly vital for understanding protein stability under varying conditions [80]. Additionally, platforms such as IBM Watson, DeepChem, and BioPharma Finder™ are utilized for real-time data analysis, optimizing process parameters, and supporting Quality-by-Design (QbD) principles by aligning formulation attributes with CQAs [136].
Furthermore, recent studies have suggested that such digital approaches contribute to accelerating biosimilar development by streamlining regulatory compliance processes, thus improving clinical effectiveness and safety profiles [7]. This technological evolution not only boosts operational efficiency but also mitigates risks in formulation processes, making a strong case for the adoption of integrated digital solutions in pharmaceutical applications [137].
The integration of digital platforms and AI-driven tools into biosimilar formulation workflows significantly improves the design, stability, and risk assessment of biosimilars. Tools such as Schrödinger’s BioLuminate can predict aggregation-prone regions using molecular dynamics simulations, thus increasing predictability in formulation outcomes [138]. Furthermore, Sartorius’ MODDE® software provides a design-based optimization approach based on experiments (DoE), merging empirical data with predictive analytics to effectively refine formulation variables [2]. Simulations Plus offers GastroPlus® and ADMET Predictor® to predict pharmacokinetic behavior and excipient compatibility. In the AI domain, AlphaFold’s capability in predicting protein structures is transformative, facilitating formulation development by anticipating structural stability challenges [138]. The deployment of IBM Watson and machine learning tools such as DeepChem enables advanced data mining and trend analysis, which aligns with the QbD framework that emphasizes rational selection of formulation attributes based on critical quality attributes [2]. Such innovations not only streamline workflows but also contribute to greater efficiency in drug development, offering a pathway to more reliable and effective biosimilar therapies.
In the fight to accelerate biosimilar production, bioprocessing innovations have driven the development of modular and flexible manufacturing systems. Single-use bioreactor systems significantly reduce the cleaning and validation time while mitigating cross-contamination risks, thereby improving overall product safety. These conditions are necessary to work with antibodies and recombinant proteins, which are inputs into the formulation of a biosimilar [139]. In this way, these systems allow rapid adaptation to diverse production requirements, aligning with the dynamic needs of the biosimilars market [37]. Furthermore, modular designs, exemplified by advances in 3D printed microfluidic systems, enhance process versatility, allowing small-scale prototyping to be rapidly transformed into low-cost, scalable production, which is an attractive feature of bioreactors [140]. Three-dimensional printed microfluidic systems in bioprocessing have significant advantages, such as precise control over fluid dynamics and the ability to monitor biochemical reactions in real time [141]. These systems enable the integration of multiple processes in a miniaturized format, leading to reduced reagent consumption and accelerated experimentation for clone selection and media optimization. The flexibility of design contributes to advanced lab-on-a-chip applications, making them ideal for high-throughput bioprocessing [142].
The integration of PAT and real-time analytics into upstream and downstream processing enhances control and consistency in bioprocessing. These approaches facilitate continuous monitoring of critical parameters such as pH and metabolite concentrations, allowing dynamic adjustments to maintain production quality and compliance with the QbD principles [143]. Furthermore, advanced chromatography techniques, such as simulated moving bed (SMB) chromatography, significantly improve the purification of biosimilars by improving selectivity and throughput, effectively addressing challenges related to product purity and consistency [144].
The formulation of biosimilars based on monoclonal antibodies and recombinant proteins is a complex process that directly determines their clinical utility by ensuring stability during storage, transport, and administration [145,146,147,148]. Precise formulation strategies, such as the use of tailored excipients and advanced stabilization techniques, not only protect protein conformation but also mitigate degradation pathways induced by physical and chemical stress [149,150,151]. An approach such as ensilication and chitosan-coated stabilizers significantly improves protein robustness, while innovative solid formulation methods offer alternatives to conventional lyophilization [152,153,154].
Chitosan-coated stabilizers have garnered significant attention in the formulation of biosimilars because of their multifaceted role in enhancing protein stability. Chitosan, a biocompatible and biodegradable polysaccharide, effectively forms a protective coating around proteins [155,156]. This coating acts as a barrier against various adverse conditions, such as aggregation and enzymatic degradation, thus maintaining the structural integrity and bioactivity of therapeutic proteins under different environmental stresses [157]. The positive charge of chitosan favors electrostatic interactions with negatively charged protein surfaces, further enhancing colloidal stability and solubility, which are critical parameters in the stability of protein formulations [158].
Furthermore, chitosan coatings can be used in nanoformulations or as excipient matrices, which are essential to extend the shelf life of biosimilars and reduce dependence on cold chain logistics [159]. The incorporation of chitosan has been reported to delay decay processes, which is vital in maintaining the quality of sensitive biological products during storage [160]. Its antimicrobial properties provide additional protection against microbial colonization, which further contributes to the stabilization of these formulations [161].
When stability technologies are explored, ensilication and lyophilization present distinct advantages and challenges. Ensilication, which involves the encapsulation of proteins within a silica matrix, protects their tertiary structures from thermal and chemical degradation, offering the potential for effective preservation at room temperature [162]. However, disadvantages include potential challenges with the complete release and recovery of protein activity postencapsulation. In contrast, lyophilization remains a well-validated technique widely accepted for protein drugs because of its ability to remove water under low pressure. This method yields a solid, stable form that retains structural integrity during long-term storage [162]. However, careful excipient design is required to minimize denaturation risks upon reconstitution [163].
The storage behavior of biosimilars is critical as even minor degradation events (e.g., oxidation, deamidation, aggregation) can significantly influence immunogenicity, potency, and pharmacokinetics [164]. To ensure product efficacy, it is imperative to conduct stability studies under the conditions recommended by the International Council for Harmonization (ICH), thus validating shelf life, transportation stability, and usability by patients. Therefore, formulation strategies must be rigorously designed to guarantee consistent quality from production to administration [165].
On the other hand, the storage behavior of high-concentration monoclonal antibodies highlights the importance of maintaining appropriate physicochemical parameters to preserve efficacy and safety [166].
Currently, numerous biosimilars derived from recombinant therapeutic proteins have emerged. Table 4 shows some of these biosimilars, with their main characteristics, which are crucial to increase competitiveness in the pharmaceutical market and improve access to quality treatments for low-income patients.
Lipid encapsulation: This technology is being explored to improve the bioavailability and stability of therapeutic proteins, particularly in liquid formulations [176].
Use of specifically designed excipients: Specific excipients are now being used to improve protein stability under adverse conditions, potentially leading to lower aggregation rates and better patient outcomes [177,178].
Advances in nanotechnology: The use of nanocarriers offers promising strategies to deliver biologics while minimizing immunogenic responses and improving therapeutic effects through targeted delivery systems [179].
Excipient formulation and selection challenges have received particular attention due to their associated risks with respect to protein stability and immunogenicity [3,6,180]. It is well established that high protein concentration formulations can cause aggregation, which can trigger adverse immune responses [178,181]. Consequently, various strategies are used to evaluate excipients and optimize formulations prior to approval [103,182,183,184]. The challenges of formulation extend to the development phase, where the assessment of excipient compatibility becomes paramount, as slight variations in these can alter the product and have significant clinical implications [37,185]. Research has shown that certain impurities can also lead to altered stability profiles and a rise or fall in immunogenic responses [103,182,183].
The development of buffer-free formulations for high-concentration biosimilars offers significant improvements in usability, particularly for subcutaneous administration. These formulations improve patient tolerability by exploiting the intrinsic buffering capacity of the protein and reducing injection site discomfort, as supported by studies that demonstrate an improved patient experience and reduced pain levels with citrate-free formulations [89]. The absence of buffer salts can mitigate the risks associated with pH instability and compatibility with device components, particularly in the context of cold chain storage [186].
Furthermore, these formulations allow for higher protein concentrations without compromising viscosity, facilitating lower injection volumes suitable for self-administration [187]. This factor is critical in improving adherence to treatment in patients, as home-based administration reduces healthcare burdens and promotes patient independence [188]. In general, these advancements underscore the potential of buffer-free biosimilars to improve patient experiences and optimize therapeutic outcomes in chronic disease management.
Innovations in excipients play a crucial role in reducing the risk of adverse reactions associated with biologic therapies. Excipients play a vital role in controlling immunogenicity during biosimilar formulation. They are selected not only for their stabilizing functions but also for their low immunogenic potential. For example, surfactants such as polysorbate 80 help prevent aggregation, while sugars (e.g., trehalose) and amino acids (e.g., histidine, arginine) stabilize tertiary structures and reduce denaturation. Replacement of citrate with polysorbate-based surfactants can prevent protein aggregation, mitigating the potential for immune responses, and improving stability [189]. Other excipients, such as trehalose, have also been used to stabilize proteins and minimize degradation, further ensuring patient comfort and safety [5]. By continuously evolving formulation strategies and improving the tolerability of biosimilars, the healthcare community can significantly enhance patient experiences and outcomes. By minimizing degradation, aggregation, and oxidation pathways, excipients help ensure consistent CQAs and reduce the likelihood of immune responses. Regulatory guidelines emphasize excipient compatibility and historical safety data, underscoring their central role in safe, patient-centered biosimilar product development.
The formulation of biologics has significantly advanced toward unbuffered or ‘self-buffering’ formulations for high-protein drugs. Unbuffered formulations have emerged as a key trend in biosimilar design aimed at mitigating immunogenicity and improving patient safety. Traditional buffer systems, while essential for maintaining protein pH levels and stability, can inadvertently induce adverse immune reactions due to protein-buffer interactions [177]. Transitioning to citrate-free or other low-buffer systems reduces these risks, while potentially improving patient comfort during administration [184,189]. The removal of citrate buffers in high-concentration biosimilars has been associated with improved patient compliance, particularly in subcutaneous administration. Citrate buffers can cause increased pain and discomfort at the injection site due to their ionic properties, which can cause a burning sensation after injection [190]. By substituting citrate with alternative buffers such as acetate or histidine, which have been shown to minimize injection site pain, manufacturers improve the overall tolerability of the biosimilar, facilitating patient self-administration and adherence to their treatment regimens [191]. Such adjustments are especially beneficial in the management of chronic conditions, often treated with long-term biologic therapies, such as autoimmune disorders and cancers, where long-term patient adherence is crucial to treatment outcomes [5].
Recent progress indicates that high protein concentrations (>50–100 mg/mL) can offer inherent pH stability, reducing dependence on traditional buffers [192,193,194]. This phenomenon is responsible for minimizing aggregation and opalescence, as evidenced by the improved stability of high-concentration protein products from spray cooling [33,195]. Furthermore, structural analysis using techniques such as small-angle X-ray scattering (SAX) has provided information on protein–protein interactions in concentrated formulations, supporting the feasibility of eliminating conventional buffering agents while forgoing stable product stability for a robust product [196].
Recent advances in protein engineering and excipient selection have enabled biosimilars to be predominantly formulated as ready-to-use liquid solutions, thus avoiding the reconstitution challenges of lyophilized products [185]. A review of 46 high-concentration antibody products revealed that 41 products are liquid formulations, a result attributed to the use of effective stabilizers such as sugars, polyols, and amino acids that mitigate protein aggregation during storage [192,193,197]. Furthermore, a structure-function approach to amphiphilic excipients has elucidated the mechanisms by which excipient-protein interactions can be optimized to enhance the stability of the solution [194]. Alternative excipients also play a decisive role in reducing degradation pathways by minimizing interfacial tensions and protein–protein interactions, thereby enhancing the stability of high-concentration formulations [33,196].
High-concentration formulations are an innovation in themselves, allowing for alternative administration routes, facilitating subcutaneous injection of high doses but in small volumes, and minimizing dependence on infusions [96,198]. As protein concentrations increase, the use of specific excipients, such as amino acids (e.g., histidine), sugars, and surfactants, is required to maintain both solubility and adequate viscosity, avoiding aggregation problems and high viscosity levels [199,200]. Furthermore, in certain cases, the high concentration itself can provide sufficient buffering capacity to dispense with some buffers, allowing citrate-free formulations. This high-concentration monoclonal antibody (mAb) formulations face significant physicochemical challenges, particularly increased viscosity and protein aggregation [198]. Elevated concentrations lead to exponential increases in viscosity, especially near the protein isoelectric point, complicating the manufacturing and syringeability for subcutaneous administration [201]. Such viscosity can also hinder the accuracy of the dose and patient comfort [199,200]. The propensity for protein aggregation, intensified by mechanical stress and thermal fluctuations, can decrease bioactivity and increase immunogenicity, thus affecting pharmacokinetics [192].
To mitigate these challenges, strategies such as optimizing pH and ionic strength, employing stabilizing excipients such as polysorbates or amino acids (arginine, histidine), and utilizing advanced formulation techniques, including lyophilization, are essential [187]. Furthermore, predictive modeling and analytical advancements now allow a better identification of regions prone to aggregation within protein structures, facilitating informed excipient selection [202]. As the industry moves toward higher concentrations (>100 mg/mL), understanding these dynamics becomes crucial for the development of effective therapeutics [192,193,194,198].
Approved biosimilar formulations generally comprise the same functional categories of excipients as their reference products, chosen to maintain protein stability and compatibility [3]. Excipients can be classified by their function as buffers to control pH (such as phosphate, histidine, or acetate), creating an optimal environment for protein integrity [148,203]. Stabilizers, such as sugars/polyols (sucrose, trehalose, and mannitol), work by replacing water molecules and mitigating aggregation, which favors protein integrity during processing and storage [148]. Surfactants, particularly polysorbate 20 or 80, which prevent surface adsorption and subsequent aggregation, which is critical for the performance of biosimilars [7]. Amino acids as stabilizers or tonicity agents (e.g., glycine, arginine, proline), chelators such as EDTA, which are antioxidant agents and contribute to the stabilization of the overall formulation by influencing the kinetics of protein unfolding and the chemical degradation pathways and contribute to the binding of metal ions, antioxidants (methionine), and tonicity modifiers such as salts [148]. High-throughput analytical approaches further validate these strategies by allowing systematic analysis of excipient compatibility and stability, thus optimizing formulation development [7,187].
Recent studies offer a broader range of insights into the roles of excipients in biosimilar formulations. Sucrose and glycerol have been shown to improve both the thermal and conformational stability of recombinant spike proteins, illustrating the critical role of sugars and polyols in formulations [204]. Solvent systems involving tert-butanol require careful optimization to maintain protein integrity, although the complexity of interactions between different components must be considered [205]. On the other hand, novel lyoprotectants, such as sweet corn phytoglycogen dendrimers, can improve protein stability during lyophilization, acting as cryoprotectants in these processes [206]. Furthermore, a very important aspect is related to the importance of monitoring polysorbate degradation in biopharmaceutical formulations, due to its importance as a surfactant [207]. Finally, lyophilized protein formulations, prioritizing patient-centered dose design, link the choice of excipient directly to the patient’s needs [208]. Table 5 illustrates the different classes of excipients commonly used in biological formulations and their functions [193].
Most biosimilars authorized to date match or intentionally simplify the formulation of the reference product to avoid the introduction of new safety variables [209].
Filgrastim biosimilars (G-CSF) use an acetate or phosphate buffer with sorbitol and polysorbate 80, very similar to the original Neupogen® formulation, which promotes protein stability and reduces the risk of immunogenicity [210,211,212,213]. Likewise, biosimilars to alfa epoetin adopt similar phosphate buffer systems and the same polysorbate stabilizing system (having removed serum albumin, as reference product, after some initial safety concerns [178]. Monoclonal antibody (mAb) biosimilars, including infliximab and rituximab, often contain the same excipients and pH as their parent compounds to ensure comparable stability and tolerability in infusion [180]. This strategic alignment of excipient profiles has been crucial to achieving clinical safety profiles similar to reference biologics, reinforcing regulatory confidence in their use [209].
Buffers deserve special attention because, while phosphate and citrate buffers are effective and have been widely used, citrate has been associated with pain and burning sensations at the injection site [214]. Citrate, a common acidic buffer, has been shown to activate acid-sensitive ion channels and induce pain after subcutaneous administration [215]. Clinical studies have shown that citrate-free and even phosphate- and glutamate-free formulations of adalimumab and other mAbs are associated with a statistically significant reduction in injection site discomfort [172,216,217]. Advances in formulation strategies have led to the successful development and approval of buffer-free monoclonal antibody (mAb) biosimilars that improve patient comfort while maintaining regulatory compliance [177,191]. A key example is the citrate-free formulation of adalimumab biosimilars such as Amjevita® (Amgen), Hadlima® (Samsung Bioepis), and Yuflyma® (Celltrion), which have received regulatory approval both in the United States and Europe [150]. These high-concentration, buffer-free formulations are associated with reduced injection site pain and increased patient adherence [216,217]. Similarly, tocilizumab biosimilars such as Tofidence® (Bio-Thera Solutions/Amgen) have introduced subcutaneous presentations with simplified buffer compositions, aligning with patient-centric design without compromising comparability standards [151]. Additionally, several trastuzumab biosimilars, including Ogivri® and Herzuma®, have employed formulations that minimize or eliminate buffers to improve tolerability and stability [152]. These products demonstrate that buffer-free innovations are not only technically feasible but are being successfully approved within stringent regulatory comparability frameworks, demonstrating bioequivalence and improved patient-reported outcomes in clinical trials [25,32]. These examples illustrate how formulation adjustments, within the limits of biosimilar comparability, can offer tangible clinical benefits [20,36].
Similarly, the amino acid L-glutamate, used in an IL-17 antibody product as a stabilizer, has been associated with injection site reactions and is generally avoided in newer formulations [218]. In addition to local tolerability, most biosimilar excipients (e.g., sugars, polysorbates) have excellent systemic safety profiles at the doses present in injections [219,220]. Virtually all excipients in approved biosimilars are ‘Generally Considered Safe’ (GRAS) substances that have been used for decades in biologics (e.g., saline, citrate, histidine, glycine, polysorbate 80, etc.) [177,221]. Manufacturers also ensure that the quality of excipients (e.g., low levels of peroxides in polysorbates to prevent protein oxidation) mitigates any risk of adverse interactions during shelf life to ensure comparability with reference products [3].
Current biologic formulations, including biosimilars, leverage refined insights into protein chemistry to improve stability, bioavailability, and reduce immunogenicity [222,223]. By carefully adjusting pH, ionic strength, and excipient selection, formulators maintain the native conformation of proteins over time. Most monoclonal antibodies (mAbs) are buffered between pH 5.0 and 6.5 to prevent aggregation near their isoelectric point and limit chemical degradation at elevated pH levels [224,225]. Excipients such as hydroxypropyl-β-cyclodextrin have been used to mitigate interfacial stress and inhibit aggregation, further stabilizing high-concentration liquid formulations [226]. This integrated approach, which considers both molecular interactions and colloidal stress factors, is critical for developing robust biologics and biosimilar formulations with improved shelf life and reduced immunogenic risk [222,223].
Modern formulations employ excipients such as sucrose or trehalose to replace water molecules around proteins, thus stabilizing tertiary structures and reducing the risk

Sections

"[{\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B1-pharmaceuticals-18-00908\", \"B2-pharmaceuticals-18-00908\", \"B3-pharmaceuticals-18-00908\", \"B4-pharmaceuticals-18-00908\", \"B5-pharmaceuticals-18-00908\", \"B6-pharmaceuticals-18-00908\", \"B7-pharmaceuticals-18-00908\", \"B7-pharmaceuticals-18-00908\", \"B8-pharmaceuticals-18-00908\", \"B9-pharmaceuticals-18-00908\", \"B10-pharmaceuticals-18-00908\", \"B11-pharmaceuticals-18-00908\", \"B12-pharmaceuticals-18-00908\"], \"section\": \"1. Introduction\", \"text\": \"Biosimilar medicines are highly sophisticated therapeutic products, specifically developed to replicate biological drugs of origin, while preserving quality, safety, and efficacy, but their intellectual property (patents) has expired [1]. Although they have similar characteristics to the source molecules, these are not identical; however, they are developed with the highest quality standards to match the safety and efficacy of the reference medicine used [2]. The process of developing biosimilars is exceptionally complex because it must address the inherent variability of recombinant proteins and ensure that any differences from the original product are clinically insignificant [3,4]. A fundamental element in the development and production of biosimilars involves the integration of advanced process design, control, and analytical characterization techniques (Quality-by-Design (QbD), Process-Analytical-Technology (PAT), in silico modeling) to anticipate immunogenic risks and optimize bioequivalence, which allows the reduction in uncertainty and simplifies regulatory reviews [5]. In the formulation of biosimilars, there are key components, including stabilizers and excipients, which must also meet the highest quality standards [6,7]. These stabilizers and excipients can profoundly influence the biopharmaceutical profile of the resulting biosimilar, which must also include the shelf life of the new medicine, as well as the method of administration, the efficacy in the treatment of patients, and the potential for immunogenicity [7,8]. Likewise, some innovations such as buffer-free formulations and nanomedicine approaches illustrate how the field of biosimilars is evolving to overcome conventional challenges while improving patient outcomes [9]. All these components, together with the inherent variability of recombinant proteins, play a fundamental role in maintaining the stability and activities of therapeutic proteins, which must be estimated from the beginning of the formulation as fundamental components of the success or failure of the final biosimilar product [10,11,12].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B1-pharmaceuticals-18-00908\", \"B2-pharmaceuticals-18-00908\", \"B13-pharmaceuticals-18-00908\", \"B14-pharmaceuticals-18-00908\", \"B15-pharmaceuticals-18-00908\", \"B16-pharmaceuticals-18-00908\", \"B17-pharmaceuticals-18-00908\", \"B18-pharmaceuticals-18-00908\", \"B19-pharmaceuticals-18-00908\", \"B20-pharmaceuticals-18-00908\", \"B21-pharmaceuticals-18-00908\", \"B22-pharmaceuticals-18-00908\"], \"section\": \"1. Introduction\", \"text\": \"In this complex dynamic, there is one crucial element to consider, that is, the expiration of intellectual property protection, which includes patents. These protect the inventors of the original biological molecules from copying for a period of two decades [1,2]. During this time, the original biological drugs enjoyed a kind of monopoly, which resulted in very high prices for low-income patients and limited their access to effective treatments [13]. Once the patent has expired, it is possible to develop and market biosimilars. Their main attraction lies in their potential to significantly reduce treatment costs without compromising quality standards, as the pharmaceutical companies that manufacture the biosimilars do not have to face royalty payments associated with patent protection or extensive clinical trials with the same duration as the originals [14,15,16,17,18,19,20]. These economic implications related to biosimilars further reinforce their relevance in the market, where they correlate with lower drug prices and increased access to proven therapies that otherwise might have been prohibitively expensive for low-income patients [21,22].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B1-pharmaceuticals-18-00908\", \"B23-pharmaceuticals-18-00908\", \"B24-pharmaceuticals-18-00908\", \"B25-pharmaceuticals-18-00908\", \"B26-pharmaceuticals-18-00908\", \"B27-pharmaceuticals-18-00908\", \"B28-pharmaceuticals-18-00908\", \"B25-pharmaceuticals-18-00908\", \"B26-pharmaceuticals-18-00908\", \"B27-pharmaceuticals-18-00908\", \"B28-pharmaceuticals-18-00908\", \"B29-pharmaceuticals-18-00908\", \"B1-pharmaceuticals-18-00908\", \"B20-pharmaceuticals-18-00908\"], \"section\": \"1. Introduction\", \"text\": \"The clinical transition from an original biological drug to a biosimilar can be positively influenced by socioeconomic factors [1]. In fact, since biosimilar products have characteristics similar to their reference counterparts, they are marketed at lower cost, among other things, because of the absence of royalties on intellectual property rights. Likewise, those who access these products generally come from communities with more restricted economic resources (as is the case in many Latin American and African countries); this would facilitate access to first-class medical treatments for these more disadvantaged communities at a much lower cost than IP-protected originals. Furthermore, cost-effectiveness analyses have shown that the strategic implementation of biosimilars could alleviate financial stress on healthcare systems, particularly in economically diverse regions [23,24]. Data reveals that biosimilars can offer substantial reductions in drug spending while maintaining therapeutic efficacy, ultimately improving patient outcomes in chronic disease management protocols [25,26]. Countries that have implemented biosimilars in their treatment protocols have achieved significant savings in final costs, which can be used to improve patient services or to cover more patients within existing budgets [27,28]. Data reveals that biosimilars can offer substantial reductions in drug spending while maintaining therapeutic efficacy, ultimately improving patient outcomes in chronic disease management protocols [25,26]. Countries that have implemented biosimilars in treatment protocols have seen significant final cost savings, which can be redirected to improve patient services or cover more patients within existing budgets [27,28]. This process contributes to the sustainability of healthcare systems by ensuring the quality, safety, and efficacy of biosimilars, optimizing the use of resources by offering more affordable alternatives to low-income patients [29]. However, despite the promising health and economic implications for patients, the complexities of biosimilar manufacturing pose specific challenges. Each biosimilar manufacturer must independently develop specialized cell lines and optimized production protocols capable of consistently producing biologically comparable products [1]. Therefore, the development of biosimilars represents both a scientific achievement and a complex regulatory challenge, highlighting the importance of maintaining strict standards of quality and efficacy as these drugs become increasingly integrated into global healthcare practices [20].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"pharmaceuticals-18-00908-t001\"], \"section\": \"1. Introduction\", \"text\": \"Biosimilars differ primarily from generic drugs in both their production and regulatory approval, as can be seen in the explanation in Table 1.\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B3-pharmaceuticals-18-00908\", \"B30-pharmaceuticals-18-00908\", \"B31-pharmaceuticals-18-00908\", \"B1-pharmaceuticals-18-00908\", \"B2-pharmaceuticals-18-00908\"], \"section\": \"1. Introduction\", \"text\": \"Therefore, generic drugs are small-molecule compounds synthesized through well-defined chemical processes that allow identical replication of the active pharmaceutical ingredient (API) [3,30,31]. This means that their regulatory approval only requires a demonstration of bioequivalence, that is, that the generic releases the same amount of API into the bloodstream as the reference product, without the need for clinical trials to evaluate efficacy or immunogenicity [1,2].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B1-pharmaceuticals-18-00908\"], \"section\": \"1. Introduction\", \"text\": \"In contrast, biosimilars are large and structurally complex proteins (typically 10,000 to 300,000 Da) produced in living cell systems using recombinant DNA technology [1]. These biological systems introduce natural variability (e.g., glycosylation, folding, impurities), making exact replication of the originator biologically impossible. Therefore, biosimilars must demonstrate high similarity, and not be identical, to their reference products. Approval is based on a stepwise comparability exercise, beginning with extensive physicochemical and functional characterization of critical quality attributes (CQA), followed by non-clinical and comparative clinical studies, particularly for immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD).\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B2-pharmaceuticals-18-00908\", \"B32-pharmaceuticals-18-00908\", \"B33-pharmaceuticals-18-00908\", \"B34-pharmaceuticals-18-00908\", \"B35-pharmaceuticals-18-00908\", \"B36-pharmaceuticals-18-00908\"], \"section\": \"1. Introduction\", \"text\": \"To ensure therapeutic equivalence, in the United States and Europe, biosimilars undergo a stepwise comparability assessment mandated by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), which includes in-depth characterization (e.g., glycosylation, folding), mechanism-of-action confirmation, and clinical immunogenicity studies. Regulatory frameworks from the EMA and FDA apply the \\u2018totality of evidence\\u2019 principle, requiring integrated data from analytical, functional, and clinical domains [2]. Furthermore, biosimilars are not automatically considered interchangeable, since separate regulatory determination is often required for substitution at the drug level, especially in jurisdictions such as the United States. This high regulatory bar reflects the complexity of biologics and the need to ensure therapeutic equivalence despite minor molecular differences. Although biosimilars share identical primary protein sequences and closely conform to three-dimensional configurations critical for biological activity, slight variations in their complex structure inevitably occur due to differences in production processes [32]. These structural nuances require strict regulatory oversight to ensure the therapeutic equivalence of biosimilars with their reference counterparts in terms of efficacy, safety, and quality [33]. Therefore, regulatory frameworks must intervene in rigorous analytical characterization, examining molecular weight, isoforms, impurity profiles, and biochemical attributes using advanced analytical technologies [34,35]. Equally important are comparative clinical studies that evaluate pharmacokinetics, pharmacodynamics, immunogenicity, and overall safety, confirming the clinical comparability of biosimilars with the original biological products [36].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B1-pharmaceuticals-18-00908\", \"B2-pharmaceuticals-18-00908\"], \"section\": \"1. Introduction\", \"text\": \"Advanced biosimilar development integrates cutting-edge design, manufacturing, and testing to meet stringent US and EU regulatory requirements. Biosimilars are approved through abbreviated regulatory pathways established by the EMA since 2005 and the FDA through the Biologics Pricing Competition and Innovation Act (BPCIA) of 2009 [1]. These frameworks require robust comparative evidence demonstrating similarity to a reference biologic in terms of quality, efficacy, and safety, while allowing reduced clinical trial burden. By 2023, more than 100 biosimilars had been approved in Europe and the US, including high-impact therapeutic areas such as oncology, rheumatology, and endocrinology [2].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B37-pharmaceuticals-18-00908\", \"B38-pharmaceuticals-18-00908\", \"B39-pharmaceuticals-18-00908\", \"B40-pharmaceuticals-18-00908\", \"B2-pharmaceuticals-18-00908\", \"B41-pharmaceuticals-18-00908\"], \"section\": \"1. Introduction\", \"text\": \"Analytical characterization, using approaches such as mass spectrometry, surface plasmon resonance, and chemometrics, is critical to establish structural and functional similarity to the reference product [37,38]. In manufacturing, different process development strategies, such as the design of experiments and PAT, facilitate important mechanistic control and characterization, ensuring product consistency during scale-up [39,40]. Regulatory pathways are increasingly using innovative analytical data and AI-based models to address various challenges, streamline comparability assessments, and reduce overreliance on large clinical trials [2]. Complementary studies demonstrate that the integration of advanced analytics and digital manufacturing improves both quality control and cost effectiveness in the final production of biosimilars [41].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B40-pharmaceuticals-18-00908\", \"B42-pharmaceuticals-18-00908\", \"B2-pharmaceuticals-18-00908\"], \"section\": \"1. Introduction\", \"text\": \"Real-time monitoring strategies such as online FTIR and Raman spectroscopy, as part of the PAT framework, ensure that critical quality attributes are maintained within acceptable limits, thus supporting the clinical performance of biosimilars [40,42]. At the same time, QbD initiatives and digital automation, supported by AI analytics, enable biosimilar manufacturers to more efficiently monitor their performance through US and EU regulations to rigorously assess comparability with reference products, optimize process development, and improve future scale-up strategies [2].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B43-pharmaceuticals-18-00908\", \"B44-pharmaceuticals-18-00908\", \"B45-pharmaceuticals-18-00908\", \"B46-pharmaceuticals-18-00908\", \"B47-pharmaceuticals-18-00908\", \"B48-pharmaceuticals-18-00908\"], \"section\": \"2. Methodology\", \"text\": \"For the documentary search, a variant of the PSALSAR methodology was used (Protocol\\u2013Search\\u2013Appraisal\\u2013Synthesis\\u2013Analysis\\u2013Report) [43]. This methodology offers a rigorous, transparent, and reproducible framework that allows an in-depth evaluation of the most representative systematic review of the literature, allowing the collection of a complete collection of documents related to the aspects investigated and that guide future scientific research [44,45,46,47,48].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B3-pharmaceuticals-18-00908\", \"B5-pharmaceuticals-18-00908\", \"B3-pharmaceuticals-18-00908\"], \"section\": \"2. Methodology\", \"text\": \"The PSALSAR methodology is applicable in the multispectral domain of biosimilar formulation research, where technological, regulatory, and legal frameworks converge. Its structured approach addresses the complex interactions between pharmaceutical formulation, regulatory science, and intellectual property, facilitating a comprehensive review of the literature that enhances methodological rigor and narrative cohesion [3,5]. Unlike traditional systematic reviews focusing solely on clinical outcomes, PSALSAR supports an argument-driven synthesis that effectively integrates formulation-related aspects such as buffer selection, along with regulatory considerations such as QbD and PAT [3]. The distinction of this methodology lies in its adaptability, which allows it to synthesize various types of content (scientific, regulatory, and legal) while allowing deeper interpretative analysis that goes beyond mere data aggregation, ultimately allowing for in-depth research into biosimilar formulations.\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B49-pharmaceuticals-18-00908\"], \"section\": \"Keywords and Document Identification Process\", \"text\": \"The methodological process began with an exploratory phase based on the research objective, in which representative keywords of the thematic domain addressed in this systematic review were defined [49]. These keywords were selected for their high scientific relevance, their ability to effectively delimit the universe of study, and their methodological usefulness in establishing inclusion and exclusion criteria, in accordance with the principles of transparency and reproducibility established by the PRISMA methodology. To guarantee effective and specific document retrieval during the identification phase, a set of strategic keywords was defined that allowed the search to be precisely and systematically guided through scientific databases and search engines with high scientific visibility, such as Scopus, Web of Science, Science Direct and Google Scholar, Core Collections, Science Direct, Compendex, Derwent, Google Scholar, Innovation Index and GeoIndex. These sources were complemented by interdisciplinary research tools that expanded the coverage and precision of the results obtained. To this end, both controlled and uncontrolled terms were integrated using Boolean operators and truncation strategies. Keywords used were the following: \\u201cBiosimilars\\u201d; \\u201cBiology\\u201d; \\u201cBiotechnology\\u201d; \\u201cHigh-concentration formulations\\u201d; \\u201cBuffer-free systems\\u201d; \\u201cImmunogenicity mitigation\\u201d; \\u201c Excipients\\u201d; \\u201cQuality by Design (QbD)\\u201d; \\u201c In silico simulations\\u201d; \\u201cProcess Analytical Technology (PAT)\\u201d; \\u201cFood and Drug Administration (FDA)\\u201d; \\u201c European Medicines Agency (EMA)\\u201d; \\u201cIntellectual property strategies (IP)\\u201d; \\u201cArtificial Intelligence (AI)\\u201d. Each of these words was selected for its relevance using \\u201cAND\\u201d and \\u201cOR\\u201d to capture the central dynamics of the object of study, covering regulatory, technological, clinical, and legal aspects linked to the development and formulation of biosimilars. Likewise, they were formulated in English to maximize coverage in the high-visibility scientific databases used.\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"pharmaceuticals-18-00908-t002\"], \"section\": \"Keywords and Document Identification Process\", \"text\": \"Table 2 provides a more detailed analysis of the inclusion and exclusion criteria used to select the references ultimately used in the research. These criteria are established prior to the bibliographic search based on the identified keywords to reduce bias and ensure that the document selection process is systematic and reproducible.\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"pharmaceuticals-18-00908-f001\"], \"section\": \"Keywords and Document Identification Process\", \"text\": \"The review process incorporates a flow chart represented in Figure 1, which illustrates the selection procedure, including the number of studies identified, selected, and involved, as well as the reasons for exclusion at each stage. The documentary strategy included a systematic review from 2019 to 2025, which resulted in a repository of 2193 documents (32 websites). This repository offers a representative sample of the state of the art on the most innovative research topic and integrates perspectives from different disciplines with an emphasis on the formulation of biosimilars in the current and future biopharmaceutical context.\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"pharmaceuticals-18-00908-t0A1\", \"B50-pharmaceuticals-18-00908\", \"B51-pharmaceuticals-18-00908\", \"B52-pharmaceuticals-18-00908\", \"B37-pharmaceuticals-18-00908\", \"B53-pharmaceuticals-18-00908\", \"B54-pharmaceuticals-18-00908\", \"B55-pharmaceuticals-18-00908\", \"B56-pharmaceuticals-18-00908\", \"B57-pharmaceuticals-18-00908\"], \"section\": \"3. Design, Manufacturing, and Analytical Characterization of Biosimilars\", \"text\": \"The design, manufacturing, and subsequent analytical characterization of biosimilars play an important role in establishing confidence in these products and in ensuring that critical quality attributes reflect those of the reference product like observed on Table A1. Biosimilar development involves not only replicating the primary amino acid sequence but also mimicking post-translational modifications such as glycosylation, which are essential to maintain clinical efficacy and safety and thus ensure that CQAs remain within acceptable ranges [50,51]. Continuous improvements in process design, including real-time monitoring and QbD initiatives, have become a cornerstone of biosimilar development [52]. The application of QbD in conjunction with the design of experiments (DoE) establishes defined control strategies and design spaces, ensuring consistent process performance and product reproducibility [37,53,54]. The use of PAT and real-time monitoring, complemented by advanced chemometric analysis, facilitates an accurate assessment of both upstream and downstream processes [55,56]. As manufacturing processes become increasingly automated and deep data-driven, the integration of machine learning for pattern recognition further improves the control of the entire process [57].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B58-pharmaceuticals-18-00908\", \"B39-pharmaceuticals-18-00908\", \"B59-pharmaceuticals-18-00908\"], \"section\": \"3. Design, Manufacturing, and Analytical Characterization of Biosimilars\", \"text\": \"Controlled downstream processing is essential for biosimilar manufacturing, as it ensures that chromatographic purification meets strict quality requirements [58]. Advanced analytical technologies, such as ultrafiltration/diafiltration and multimodal chromatography, facilitate the high-resolution separation of aggregates and impurities from the process, thus improving the purification accuracy during scale-up [39,59].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B60-pharmaceuticals-18-00908\"], \"section\": \"3.1. Analytical Characterization and Processing Strategies of Biosimilars\", \"text\": \"Post-translational modifications (PTMs), such as glycosylation, phosphorylation, deamidation, and oxidation, significantly influence the stability, efficacy, and immunogenicity of biologics, including biosimilars. Unlike conventional drugs, biosimilars are produced in living cells, leading to variability in PTM profiles, which can impact critical aspects such as receptor binding, clearance rates, and antibody-dependent cellular cytotoxicity (ADCC) [60].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B61-pharmaceuticals-18-00908\", \"B62-pharmaceuticals-18-00908\", \"B63-pharmaceuticals-18-00908\"], \"section\": \"3.1. Analytical Characterization and Processing Strategies of Biosimilars\", \"text\": \"The achievement of consistent PTM profiles is complex due to the different expression systems and the variable bioprocessing conditions, which require advanced analytical techniques such as liquid chromatography tandem mass spectrometry (LC-MS/MS) and capillary electrophoresis for thorough characterization [61]. Immunogenicity remains a concern, as even slight differences in PTM can provoke adverse immune responses, potentially compromising therapeutic effectiveness [62]. Even small differences in glycosylation profiles (e.g., sialylation or fucosylation) can alter pharmacokinetics and affect receptor binding affinity, clearance rates, and effector functions such as antibody-dependent cell cytotoxicity (ADCC) [63].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B64-pharmaceuticals-18-00908\", \"B65-pharmaceuticals-18-00908\"], \"section\": \"3.1. Analytical Characterization and Processing Strategies of Biosimilars\", \"text\": \"These factors mean that biosimilar developers must implement advanced analytical technologies (e.g., LC-MS/MS, capillary electrophoresis) to rigorously characterize PTMs and demonstrate high similarity to the reference product [64,65].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B66-pharmaceuticals-18-00908\", \"B67-pharmaceuticals-18-00908\", \"B68-pharmaceuticals-18-00908\"], \"section\": \"3.1. Analytical Characterization and Processing Strategies of Biosimilars\", \"text\": \"Regulatory bodies (FDA and EMA) demand comprehensive comparative studies that assess immunogenicity, recognizing the importance of minimizing aggregates and choosing appropriate excipients [66,67,68].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B69-pharmaceuticals-18-00908\", \"B70-pharmaceuticals-18-00908\"], \"section\": \"3.1. Analytical Characterization and Processing Strategies of Biosimilars\", \"text\": \"The formulation and long-term performance of biosimilars are crucial to their therapeutic success in a highly competitive industry. Molecular design in biosimilar development emphasizes engineering expression systems that closely resemble the reference biologic. Techniques such as optimizing codon usage and designing suitable signal peptides are vital to achieve biochemical equivalence with the innovator [69]. However, due to the inherent complexity of biologics, the achievement of identical molecular structures is implausible. Instead, a rational engineering approach focuses on replicating functional domains that dictate therapeutic efficacy [70].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B71-pharmaceuticals-18-00908\", \"B72-pharmaceuticals-18-00908\", \"B73-pharmaceuticals-18-00908\"], \"section\": \"3.1. Analytical Characterization and Processing Strategies of Biosimilars\", \"text\": \"Reproducing PTMs, especially glycosylation, is particularly challenging. As PTMs significantly influence the pharmacokinetics and immunogenicity of biologics, meticulous control over production conditions is necessary [71]. Advanced analytical techniques, including LC-MS and HILIC, facilitate comparative glycosylation profiling, which is essential to establish biosimilarity [72]. Furthermore, strategies such as the use of nanoparticles for stabilization hold promise to enhance the delivery and efficacy of sensitive biosimilar products [73].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B74-pharmaceuticals-18-00908\", \"B2-pharmaceuticals-18-00908\", \"B75-pharmaceuticals-18-00908\"], \"section\": \"3.1. Analytical Characterization and Processing Strategies of Biosimilars\", \"text\": \"Molecular design in biosimilar development requires meticulous attention to protein structure and function, particularly focusing on how recombinant expression systems and upstream processes can replicate the characteristics of reference biologics [74]. This intricate process emphasizes the role of signal peptides in facilitating proper protein folding, the optimization of codon usage for effective expression in host cells, and the selection of appropriate expression systems to closely align with the glycosylation profiles of the reference products. While achieving complete molecular identity is unattainable due to the inherent complexities of biologic synthesis, molecular engineering strategies aim to reproduce the key functional domains critical for therapeutic activity and receptor interaction [2,75].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B76-pharmaceuticals-18-00908\", \"B77-pharmaceuticals-18-00908\", \"B78-pharmaceuticals-18-00908\"], \"section\": \"3.1. Analytical Characterization and Processing Strategies of Biosimilars\", \"text\": \"The creation of biosimilars must account for variations in PTMs, with glycosylation being one of the most significant challenges faced in this developmental landscape. Glycans, which are carbohydrate structures attached to proteins, can affect the biological function, stability, immunogenicity, and half-life of the resultant biosimilars. This complexity arises from the sensitivity of glycosylation to cellular environments, including cell type, medium composition, culture conditions, and purification processes, which can dramatically influence glycan structure [76]. As such, developers utilize orthogonal methods alongside extensive CQA modeling to verify that the PTM profiles align closely with those of the reference biologic [77,78].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B72-pharmaceuticals-18-00908\", \"B79-pharmaceuticals-18-00908\", \"B68-pharmaceuticals-18-00908\"], \"section\": \"3.1. Analytical Characterization and Processing Strategies of Biosimilars\", \"text\": \"Advanced analytical techniques such as liquid chromatography mass spectrometry (LC-MS), nuclear magnetic resonance (NMR), and high-resolution chromatography play critical roles in ensuring that the molecular architecture and post-translational landscapes of biosimilars are consistent and comparable to their reference products. These methodologies facilitate detailed examination and characterization of glycosylation patterns and other critical quality attributes, supporting rigorous testing and validation protocols that are essential for regulatory approval [72,79]. For example, methods such as mass spectrometry allow precision in identifying glycosylation sites and structures, thus confirming conformity to established specifications set by authorities such as the FDA [68].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B2-pharmaceuticals-18-00908\", \"B80-pharmaceuticals-18-00908\"], \"section\": \"3.1. Analytical Characterization and Processing Strategies of Biosimilars\", \"text\": \"The variability inherent in PTMs necessitates a robust approach to verifying these modifications, as even minor discrepancies can translate into considerable differences in therapeutic efficacy and safety profiles. Researchers have proposed using sophisticated algorithms and automation to streamline the analyses of glycosylation and other PTMs during the biosimilar development process. This could improve the reliability of assessing biosimilarity and contribute to more consistent product quality [2,80].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B81-pharmaceuticals-18-00908\"], \"section\": \"3.1. Analytical Characterization and Processing Strategies of Biosimilars\", \"text\": \"Although challenges remain with respect to glycosylation consistency, advancements in nanomedicine also present exciting avenues for addressing the stability and delivery of biosimilars. Nanotechnology, which includes approaches such as nanoparticle encapsulation or liposomal carriers, serves to protect sensitive biologics from environmental degradation while enabling sustained release mechanisms. Such strategies can potentially mitigate issues related to immunogenicity while also improving pharmacokinetic profiles [81]. The ongoing integration of nanotechnology into biosimilar formulations reflects a growing recognition of the potential it holds for the next generation of therapeutic interventions.\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B69-pharmaceuticals-18-00908\", \"B82-pharmaceuticals-18-00908\", \"B83-pharmaceuticals-18-00908\"], \"section\": \"3.1. Analytical Characterization and Processing Strategies of Biosimilars\", \"text\": \"Moreover, through ongoing research into glycomic profiling and enhanced production techniques, it is increasingly plausible to generate biosimilars that mimic their originators more closely. This includes the manipulation of culture conditions, bioreactor designs, and even the use of plant-based production systems that facilitate the expression of complex glycosylated proteins [69,82]. Innovative analytical strategies will continue to evolve, providing pathways to not only replicate but also optimize these characteristics dynamically throughout the development process [83].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B84-pharmaceuticals-18-00908\", \"B85-pharmaceuticals-18-00908\", \"B86-pharmaceuticals-18-00908\"], \"section\": \"3.1. Analytical Characterization and Processing Strategies of Biosimilars\", \"text\": \"The regulatory landscape remains a key component in the development and approval of biosimilars. Authorities are focused on ensuring that these products not only meet safety and efficacy benchmarks but also provide transparency and consistency in quality control [84]. With continuing advancements in biotechnology and analytical methods, along with strong regulatory frameworks, the outlook for biosimilars appears promising. The convergence of rigorous analytical methodologies and innovative molecular design will be crucial in the delivery of clinically effective and safe biosimilar therapies to patients around the world [85,86].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B37-pharmaceuticals-18-00908\", \"B87-pharmaceuticals-18-00908\", \"B88-pharmaceuticals-18-00908\", \"B37-pharmaceuticals-18-00908\", \"B50-pharmaceuticals-18-00908\", \"B89-pharmaceuticals-18-00908\", \"B21-pharmaceuticals-18-00908\", \"B90-pharmaceuticals-18-00908\", \"B91-pharmaceuticals-18-00908\", \"B92-pharmaceuticals-18-00908\", \"B93-pharmaceuticals-18-00908\", \"B94-pharmaceuticals-18-00908\"], \"section\": \"3.1. Analytical Characterization and Processing Strategies of Biosimilars\", \"text\": \"The analytical characterization of biosimilars has become increasingly sophisticated with the implementation of orthogonal techniques that investigate various aspects of molecular structure [37]. This employs an integrated \\u2018totality of evidence\\u2019 strategy that uses high resolution mass spectrometry, as well as multidimensional LC-MS (or liquid chromatography coupled to multidimensional mass spectrometry), which is an advanced analytical technique that combines several chromatographic separation steps with mass spectrometry (MS) to achieve a more precise, in-depth, and complete characterization of complex chemical mixtures, such as proteins, metabolites, lipids or natural extracts [87]. LC-MS methods enable high-resolution analysis of intact proteins, peptide mapping, and glycan profiling in a single workflow [88]. This multiplexing capability is essential for biosimilars, where even small differences in post-translational modification patterns can have significant immunogenic implications. Orthogonal approaches ensure that differences in charge variants and glycan profiles, which are critical quality attributes, remain within acceptable ranges as required by regulatory authorities in both the United States and Europe [37,50,89]. Advanced nuclear magnetic resonance spectroscopy (NMR) techniques, bidirectional heteronuclear (bidirectional heteronuclear NMR or bidirectional heteronuclear correlation NMR), which is a specialized NMR technique that correlates nuclei of different chemical elements to more accurately analyze molecular structure, allowing to analyze how distinct nuclei connect in both directions within a molecule [21]. All these techniques facilitate a deeper understanding of the chemical structure and are especially valuable in complex structural analyses such as those of biomolecules, improving spectral interpretation and assignment to reveal subtle variations in glycosylation and higher order structures [90,91,92]. Furthermore, statistical methods such as bootstrapping tests have improved confidence in biosimilarity assessments, ensuring batch-to-batch consistency and mitigating process-induced variations [93]. Together, these advanced physicochemical and functional analyses support the reliable development of biosimilars by providing a robust framework for confirming safety and efficacy at the molecular level [94].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B95-pharmaceuticals-18-00908\", \"B40-pharmaceuticals-18-00908\", \"B96-pharmaceuticals-18-00908\", \"B97-pharmaceuticals-18-00908\", \"B98-pharmaceuticals-18-00908\", \"B3-pharmaceuticals-18-00908\"], \"section\": \"3.2. Different Strategies and Processing Advances in the Manufacture of Biosimilars\", \"text\": \"Advances in manufacturing also include the adoption of continuous processing strategies and real-time release testing enabled by PAT. Advances in manufacturing have benefited significantly from the integration of miniaturized PAT into continuous processing systems [95]. These advances enable the real-time detection of critical quality attributes such as protein aggregates and glycosylation variants, facilitating the implementation of immediate corrective actions and reducing batch-to-batch variability [40,96]. Incorporation of online tools, such as Raman spectroscopy, facilitates process monitoring, ensuring that design deviations are addressed quickly [97,98]. Biosimilar analysis similarity assessments are now recognized as a comprehensive exercise that focuses not only on physicochemical properties but also on functional performance of the molecule [3]. Some novel methods were used, including multifaceted bioassays and cell-based studies, to assess biological activity against the reference product. Such studies are vital for the acceptance of biosimilars by regulatory authorities in both the US and European markets as they establish a direct link between manufacturing quality and clinical outcomes. This \\u2018totality of evidence\\u2019 approach ensures that any subtle manufacturing differences do not translate into clinically meaningful differences.\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B99-pharmaceuticals-18-00908\", \"B100-pharmaceuticals-18-00908\", \"B101-pharmaceuticals-18-00908\"], \"section\": \"3.2. Different Strategies and Processing Advances in the Manufacture of Biosimilars\", \"text\": \"QbD is integral to biosimilar manufacturing, as it emphasizes the identification of critical quality attributes (CQAs) and their alignment with critical process parameters (CPPs). This strategic change enhances the robustness of the production process, mitigating variability and ensuring that the biosimilar meets regulatory requirements [99,100]. Furthermore, PAT improves QbD by allowing continuous real-time monitoring of critical parameters during manufacturing, ensuring consistent quality between batches [101].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B53-pharmaceuticals-18-00908\"], \"section\": \"3.2. Different Strategies and Processing Advances in the Manufacture of Biosimilars\", \"text\": \"Glycosylation is crucial for the characterization of biosimilars, significantly influencing their pharmacokinetics, efficacy, and immunogenicity. Regulatory authorities require comprehensive glycan profiling through advanced analytical techniques to establish bioactivity and comparability with the reference product, reinforcing the importance of glycosylation in the evaluation of biosimilars [53]. Collectively, QbD, PAT, and glycosylation profiling are pivotal in supporting the development of safe and effective biosimilars that meet stringent regulatory standards.\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B102-pharmaceuticals-18-00908\"], \"section\": \"3.2. Different Strategies and Processing Advances in the Manufacture of Biosimilars\", \"text\": \"Furthermore, advanced end-point assays such as multiangle light scattering (MALS), differential scanning calorimetry (DSC), and dynamic light scattering (DLS) have improved the ability to monitor biosimilar thermal and colloidal stability, as well as aggregates and subtle conformational changes induced by manufacturing stress, thus ensuring batch consistency and strengthening quality control during process validation [102].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B103-pharmaceuticals-18-00908\"], \"section\": \"3.2. Different Strategies and Processing Advances in the Manufacture of Biosimilars\", \"text\": \"Orthogonal analytical approaches are vital in verifying biosimilarity due to the complexities inherent in biological products. These approaches utilize multiple independent methods, such as DSC, MALS, and DLS, to assess critical attributes of biosimilars. When employing these diverse techniques, the risk of bias of a single method is mitigated, thus strengthening the validity of claims of biosimilarity [103].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B104-pharmaceuticals-18-00908\", \"B105-pharmaceuticals-18-00908\", \"B37-pharmaceuticals-18-00908\", \"B103-pharmaceuticals-18-00908\"], \"section\": \"3.2. Different Strategies and Processing Advances in the Manufacture of Biosimilars\", \"text\": \"DSC measures the thermal transitions of proteins, providing insight into their thermal stability and folding integrity, which are essential for confirming identical functional characteristics between a biosimilar and its reference product [104]. MALS, combined with size-exclusion chromatography, enables the determination of absolute molecular weight and aggregation state, critical for ensuring physicochemical equivalence [105]. DLS focuses on the size distribution and colloidal stability of particles, allowing for early detection of aggregation phenomena that could affect therapeutic efficacy [37,103].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B5-pharmaceuticals-18-00908\", \"B106-pharmaceuticals-18-00908\"], \"section\": \"3.2. Different Strategies and Processing Advances in the Manufacture of Biosimilars\", \"text\": \"Together, these techniques provide a comprehensive dataset that supports regulatory compliance and the totality-of-evidence approach mandated by regulatory agencies, ultimately facilitating the biosimilar approval process [5,106].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B107-pharmaceuticals-18-00908\", \"B108-pharmaceuticals-18-00908\"], \"section\": \"3.2. Different Strategies and Processing Advances in the Manufacture of Biosimilars\", \"text\": \"Integration of these orthogonal assays with high-resolution structural characterization methods, particularly X-ray crystallography and cryoelectron microscopy, further allows detailed mapping of the 3D conformation of the protein, crucial for verifying biosimilarity and shelf-life stability [107,108].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"pharmaceuticals-18-00908-f002\"], \"section\": \"3.2. Different Strategies and Processing Advances in the Manufacture of Biosimilars\", \"text\": \"To facilitate a practical understanding of how digital tools integrate with regulatory-aligned formulation design, Figure 2 illustrates a stepwise flow of QbD\\u2013PAT\\u2013AI integration in biosimilar development. This system approach enables real-time feedback, rational formulation optimization, and predictive analytics for critical quality attributes.\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"pharmaceuticals-18-00908-t003\", \"pharmaceuticals-18-00908-f002\"], \"section\": \"3.2. Different Strategies and Processing Advances in the Manufacture of Biosimilars\", \"text\": \"Table 3 complements Figure 2, allowing a more detailed understanding of the sequential steps and digital tools involved in the workflow of integrated biosimilar formulation with QbD-PAT-IA.\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B2-pharmaceuticals-18-00908\", \"B37-pharmaceuticals-18-00908\", \"B109-pharmaceuticals-18-00908\", \"B110-pharmaceuticals-18-00908\", \"B111-pharmaceuticals-18-00908\", \"B112-pharmaceuticals-18-00908\", \"B2-pharmaceuticals-18-00908\", \"B113-pharmaceuticals-18-00908\", \"B37-pharmaceuticals-18-00908\", \"B114-pharmaceuticals-18-00908\", \"B115-pharmaceuticals-18-00908\", \"B115-pharmaceuticals-18-00908\", \"B116-pharmaceuticals-18-00908\", \"B117-pharmaceuticals-18-00908\", \"B101-pharmaceuticals-18-00908\", \"B118-pharmaceuticals-18-00908\"], \"section\": \"3.3. Integrating AI and Machine Learning into the Biosimilar Development Process\", \"text\": \"The integration of AI and machine learning is transforming biosimilar development by analyzing large-scale manufacturing and datasets to predict critical quality attributes and detect process anomalies early [2,37,109]. AI-based systems improve process design by facilitating predictive quality assessments like those developed for originator manufacturing, now extending to analytical similarity of biosimilars and optimization of culture media [110]. Moreover, by evaluating parameters such as glycosylation patterns, these computational tools support robust process validation and agility in production environments, ensuring that product quality consistently meets regulatory standards [111,112]. AI facilitates real-time process monitoring and control in biosimilar production by integrating advanced analytics with PAT systems to analyze bioprocess data streams, improving adaptive feedback mechanisms that minimize variability and optimize yields [2,113]. Although still in the early stages, the convergence of these advanced techniques promises to optimize process variables, thereby reducing deviations and accelerating scale-up while advancing quality control measures in biosimilar development [37,114]. Integration of digital tools and AI in the formulation of predictive models and in silico simulations represents a transformative advance that spans multiple sectors, from the discovery of new drugs to the optimization of industrial processes. Recent advances in AI, such as the multihead attention-based drug repurposing recommendation network (MRNDR) model, demonstrate the potential of multihead attention mechanisms in the prediction of complex biological interactions [115]. The model uses a large-scale dataset and advanced machine learning techniques to predict drug-disease relationships, achieving state-of-the-art performance metrics. Although the primary focus is drug repurposing, the methodologies employed, such as multi-head self-attention mechanisms and weighted representation distance scoring, are relevant to biosimilar formulation optimization. These techniques can improve the prediction of protein stability, aggregation propensity, and immunogenicity, which are critical factors in the development of biosimilars. While MRNDR is primarily applied to drug repurposing, its underlying architecture can be adapted to predict critical quality attributes in biosimilar formulations, thus enhancing the efficiency and accuracy of formulation development processes. This convergence is based on the ability to create digital twins that replicate the behavior of real systems in virtual environments, allowing the simulation, analysis, and prediction of different scenarios without incurring high costs and risks inherent to physical tests [115,116,117]. In biosimilar development, a digital twin is used, representing a virtual real-time replica of the bioprocess derived from mechanistic models and sensor data, to simulate and predict the impact of process changes on CQAs before execution, streamlining the QbD approach [101,118].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B2-pharmaceuticals-18-00908\", \"B119-pharmaceuticals-18-00908\", \"B120-pharmaceuticals-18-00908\", \"B121-pharmaceuticals-18-00908\", \"B122-pharmaceuticals-18-00908\", \"B123-pharmaceuticals-18-00908\", \"B124-pharmaceuticals-18-00908\", \"B125-pharmaceuticals-18-00908\", \"B126-pharmaceuticals-18-00908\", \"B127-pharmaceuticals-18-00908\", \"B128-pharmaceuticals-18-00908\"], \"section\": \"3.3. Integrating AI and Machine Learning into the Biosimilar Development Process\", \"text\": \"Deep learning models, particularly convolutional neural networks (CNNs) and recurrent neural networks (RNNs), play a significant role in forecasting protein aggregation during formulation processes. By analyzing large datasets of molecular structures and properties, these models can effectively identify aggregation-prone regions, helping guide excipient selection and thus mitigate immunogenicity risks and improve biosimilar stability over time [2,119]. In the pharmaceutical field, the use of transformer-based models has been developed to estimate drug-target interactions, significantly optimizing the discovery and validation process of potential compounds [120]. Approaches used in silico for the design and prediction of aptamers improve efficiency in the identification of biomarkers and therapeutic optimization [121]. In silico simulations allow exploring multiple scales, from molecular processes to macrolevel systems, using mathematical modeling methods combined with AI algorithms. These techniques have been extended to the simulation of complex interactions in antibody-based therapies, where the integration of multiscale models is crucial to understand the relationship between molecular structure and process behavior at the production level [122]. In silico simulations are increasingly pivotal in the design of aptamers and in the optimization of therapeutic processes. By employing molecular coupling and dynamic simulation algorithms, researchers can accurately predict aptamer-target interactions, refine binding affinities, and enhance target specificity without extensive physical experimentation, thus streamlining the development of these biomolecules for therapeutic purposes [123]. This modeling approach not only reduces costs and time but also helps in the preassessment of aptamer viability as diagnostic tools or therapeutic agents. Predictive modeling is crucial for scaling up biosimilar manufacturing because pilot-scale performance often does not translate directly to larger scales. Mechanistic and statistical models simulate critical bioprocess variables, such as shear stress and oxygen transfer rates, enabling developers to anticipate quality attributes and operational challenges before industrial implementation [124]. This predictive capacity minimizes risks, improving the reliability and efficiency of scaling operations. Single-use bioreactors enhance the safety of biosimilar production by significantly reducing cross-contamination risks associated with traditional systems. Their design eliminates the need for extensive cleaning and sterilization procedures between batches, promoting contamination control and operational efficiency, particularly in multiproduct facilities [125]. By facilitating rapid changeovers and offering greater flexibility, single-use systems support agile manufacturing practices essential for modern biosimilar production. Integrating \\u2018in silico\\u2019 approaches in drug discovery not only reduces the time and cost of experimental testing but also allows the prediction of complex behaviors and iterative adjustment of designs [126]. In this context, the application of silico models not only allows simulation of complex scenarios at different scales but also improves the efficiency and effectiveness of the development process by reducing experimentation time and associated costs and facilitating early validation of hypotheses before physical implementation [127,128].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B129-pharmaceuticals-18-00908\", \"B130-pharmaceuticals-18-00908\", \"B131-pharmaceuticals-18-00908\", \"B128-pharmaceuticals-18-00908\", \"B132-pharmaceuticals-18-00908\"], \"section\": \"3.3. Integrating AI and Machine Learning into the Biosimilar Development Process\", \"text\": \"Advances in deep learning, particularly in the application of graph neural networks (GNNs), have proven to be very important in modeling molecular structures and predicting their properties with high precision [129,130]. Similarly, a multiscale graph neural network model that integrates features at different levels of the molecular structure to predict properties with comparable or superior performance compared to other methods [131]. These approaches allow for a detailed characterization of the molecular structure, offering a solid basis for optimization in the development of biosimilars [128]. The use of GNN-based approaches to map protein-protein interfaces allows us to optimize the compatibility and functionality of biosimilars by predicting critical molecular interactions [132].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B133-pharmaceuticals-18-00908\", \"B134-pharmaceuticals-18-00908\"], \"section\": \"3.3. Integrating AI and Machine Learning into the Biosimilar Development Process\", \"text\": \"Another crucial aspect is the improvement in the accuracy of predictive models through the fusion of deep learning techniques. learning e, 3D structural information. By incorporating graph neural networks together with models based on three-dimensional structure, it is possible to predict the binding affinity between ligands and proteins more accurately [133]. This methodology is especially relevant in the context of biosimilars, where optimization of molecular interactions directly influences therapeutic efficacy and similarity. Similarly, encoder\\u2013decoder models improve target-directed design, accelerating the identification of desired molecular profiles and reducing uncertainty at critical stages of development [134].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B135-pharmaceuticals-18-00908\", \"B80-pharmaceuticals-18-00908\", \"B136-pharmaceuticals-18-00908\"], \"section\": \"3.3. Integrating AI and Machine Learning into the Biosimilar Development Process\", \"text\": \"Integration of digital platforms and AI tools into biosimilar formulation workflows enhances molecular stability and design efficiency. For example, simulations such as GastroPlus\\u00ae and ADMET Predictor\\u00ae by Simulations Plus facilitate pharmacokinetic predictions and excipient compatibility assessments, which are crucial for biopharmaceutical developments [135]. AI advancements, particularly AlphaFold\\u2019s ability to predict protein structures, are increasingly vital for understanding protein stability under varying conditions [80]. Additionally, platforms such as IBM Watson, DeepChem, and BioPharma Finder\\u2122 are utilized for real-time data analysis, optimizing process parameters, and supporting Quality-by-Design (QbD) principles by aligning formulation attributes with CQAs [136].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B7-pharmaceuticals-18-00908\", \"B137-pharmaceuticals-18-00908\"], \"section\": \"3.3. Integrating AI and Machine Learning into the Biosimilar Development Process\", \"text\": \"Furthermore, recent studies have suggested that such digital approaches contribute to accelerating biosimilar development by streamlining regulatory compliance processes, thus improving clinical effectiveness and safety profiles [7]. This technological evolution not only boosts operational efficiency but also mitigates risks in formulation processes, making a strong case for the adoption of integrated digital solutions in pharmaceutical applications [137].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B138-pharmaceuticals-18-00908\", \"B2-pharmaceuticals-18-00908\", \"B138-pharmaceuticals-18-00908\", \"B2-pharmaceuticals-18-00908\"], \"section\": \"3.3. Integrating AI and Machine Learning into the Biosimilar Development Process\", \"text\": \"The integration of digital platforms and AI-driven tools into biosimilar formulation workflows significantly improves the design, stability, and risk assessment of biosimilars. Tools such as Schr\\u00f6dinger\\u2019s BioLuminate can predict aggregation-prone regions using molecular dynamics simulations, thus increasing predictability in formulation outcomes [138]. Furthermore, Sartorius\\u2019 MODDE\\u00ae software provides a design-based optimization approach based on experiments (DoE), merging empirical data with predictive analytics to effectively refine formulation variables [2]. Simulations Plus offers GastroPlus\\u00ae and ADMET Predictor\\u00ae to predict pharmacokinetic behavior and excipient compatibility. In the AI domain, AlphaFold\\u2019s capability in predicting protein structures is transformative, facilitating formulation development by anticipating structural stability challenges [138]. The deployment of IBM Watson and machine learning tools such as DeepChem enables advanced data mining and trend analysis, which aligns with the QbD framework that emphasizes rational selection of formulation attributes based on critical quality attributes [2]. Such innovations not only streamline workflows but also contribute to greater efficiency in drug development, offering a pathway to more reliable and effective biosimilar therapies.\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B139-pharmaceuticals-18-00908\", \"B37-pharmaceuticals-18-00908\", \"B140-pharmaceuticals-18-00908\", \"B141-pharmaceuticals-18-00908\", \"B142-pharmaceuticals-18-00908\"], \"section\": \"3.4. Innovations in the Field of Bioprocessing\", \"text\": \"In the fight to accelerate biosimilar production, bioprocessing innovations have driven the development of modular and flexible manufacturing systems. Single-use bioreactor systems significantly reduce the cleaning and validation time while mitigating cross-contamination risks, thereby improving overall product safety. These conditions are necessary to work with antibodies and recombinant proteins, which are inputs into the formulation of a biosimilar [139]. In this way, these systems allow rapid adaptation to diverse production requirements, aligning with the dynamic needs of the biosimilars market [37]. Furthermore, modular designs, exemplified by advances in 3D printed microfluidic systems, enhance process versatility, allowing small-scale prototyping to be rapidly transformed into low-cost, scalable production, which is an attractive feature of bioreactors [140]. Three-dimensional printed microfluidic systems in bioprocessing have significant advantages, such as precise control over fluid dynamics and the ability to monitor biochemical reactions in real time [141]. These systems enable the integration of multiple processes in a miniaturized format, leading to reduced reagent consumption and accelerated experimentation for clone selection and media optimization. The flexibility of design contributes to advanced lab-on-a-chip applications, making them ideal for high-throughput bioprocessing [142].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B143-pharmaceuticals-18-00908\", \"B144-pharmaceuticals-18-00908\"], \"section\": \"3.4. Innovations in the Field of Bioprocessing\", \"text\": \"The integration of PAT and real-time analytics into upstream and downstream processing enhances control and consistency in bioprocessing. These approaches facilitate continuous monitoring of critical parameters such as pH and metabolite concentrations, allowing dynamic adjustments to maintain production quality and compliance with the QbD principles [143]. Furthermore, advanced chromatography techniques, such as simulated moving bed (SMB) chromatography, significantly improve the purification of biosimilars by improving selectivity and throughput, effectively addressing challenges related to product purity and consistency [144].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B145-pharmaceuticals-18-00908\", \"B146-pharmaceuticals-18-00908\", \"B147-pharmaceuticals-18-00908\", \"B148-pharmaceuticals-18-00908\", \"B149-pharmaceuticals-18-00908\", \"B150-pharmaceuticals-18-00908\", \"B151-pharmaceuticals-18-00908\", \"B152-pharmaceuticals-18-00908\", \"B153-pharmaceuticals-18-00908\", \"B154-pharmaceuticals-18-00908\"], \"section\": \"4. Biosimilar Formulations Based on Monoclonal Antibodies and Recombinant Proteins\", \"text\": \"The formulation of biosimilars based on monoclonal antibodies and recombinant proteins is a complex process that directly determines their clinical utility by ensuring stability during storage, transport, and administration [145,146,147,148]. Precise formulation strategies, such as the use of tailored excipients and advanced stabilization techniques, not only protect protein conformation but also mitigate degradation pathways induced by physical and chemical stress [149,150,151]. An approach such as ensilication and chitosan-coated stabilizers significantly improves protein robustness, while innovative solid formulation methods offer alternatives to conventional lyophilization [152,153,154].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B155-pharmaceuticals-18-00908\", \"B156-pharmaceuticals-18-00908\", \"B157-pharmaceuticals-18-00908\", \"B158-pharmaceuticals-18-00908\"], \"section\": \"4. Biosimilar Formulations Based on Monoclonal Antibodies and Recombinant Proteins\", \"text\": \"Chitosan-coated stabilizers have garnered significant attention in the formulation of biosimilars because of their multifaceted role in enhancing protein stability. Chitosan, a biocompatible and biodegradable polysaccharide, effectively forms a protective coating around proteins [155,156]. This coating acts as a barrier against various adverse conditions, such as aggregation and enzymatic degradation, thus maintaining the structural integrity and bioactivity of therapeutic proteins under different environmental stresses [157]. The positive charge of chitosan favors electrostatic interactions with negatively charged protein surfaces, further enhancing colloidal stability and solubility, which are critical parameters in the stability of protein formulations [158].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B159-pharmaceuticals-18-00908\", \"B160-pharmaceuticals-18-00908\", \"B161-pharmaceuticals-18-00908\"], \"section\": \"4. Biosimilar Formulations Based on Monoclonal Antibodies and Recombinant Proteins\", \"text\": \"Furthermore, chitosan coatings can be used in nanoformulations or as excipient matrices, which are essential to extend the shelf life of biosimilars and reduce dependence on cold chain logistics [159]. The incorporation of chitosan has been reported to delay decay processes, which is vital in maintaining the quality of sensitive biological products during storage [160]. Its antimicrobial properties provide additional protection against microbial colonization, which further contributes to the stabilization of these formulations [161].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B162-pharmaceuticals-18-00908\", \"B162-pharmaceuticals-18-00908\", \"B163-pharmaceuticals-18-00908\"], \"section\": \"4. Biosimilar Formulations Based on Monoclonal Antibodies and Recombinant Proteins\", \"text\": \"When stability technologies are explored, ensilication and lyophilization present distinct advantages and challenges. Ensilication, which involves the encapsulation of proteins within a silica matrix, protects their tertiary structures from thermal and chemical degradation, offering the potential for effective preservation at room temperature [162]. However, disadvantages include potential challenges with the complete release and recovery of protein activity postencapsulation. In contrast, lyophilization remains a well-validated technique widely accepted for protein drugs because of its ability to remove water under low pressure. This method yields a solid, stable form that retains structural integrity during long-term storage [162]. However, careful excipient design is required to minimize denaturation risks upon reconstitution [163].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B164-pharmaceuticals-18-00908\", \"B165-pharmaceuticals-18-00908\"], \"section\": \"4. Biosimilar Formulations Based on Monoclonal Antibodies and Recombinant Proteins\", \"text\": \"The storage behavior of biosimilars is critical as even minor degradation events (e.g., oxidation, deamidation, aggregation) can significantly influence immunogenicity, potency, and pharmacokinetics [164]. To ensure product efficacy, it is imperative to conduct stability studies under the conditions recommended by the International Council for Harmonization (ICH), thus validating shelf life, transportation stability, and usability by patients. Therefore, formulation strategies must be rigorously designed to guarantee consistent quality from production to administration [165].\"}, {\"pmc\": \"PMC12196224\", \"pmid\": \"\", \"reference_ids\": [\"B166-pharmaceuticals-18-00908\"], \"section\": \"4. Biosimilar Formulations Based on Monoclonal Antibodies and Recombinant Pr

Metadata

"{}"